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Summary 
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by 
mutations in the dystrophin gene that cause the absence of the dystrophin 
protein at the muscle fiber membrane of the affected patients. This leads to 
myofiber degeneration and progressive muscle wasting, ultimately resulting in 
significant morbidity and mortality. Currently, there is no treatment that prevents 
or reverses the disease progression. Genetically corrected stem/progenitor cells 
could potentially provide an effective treatment. However, due to its large size, 
commonly used viral vector technologies preclude efficient gene transfer of the 
full-length dystrophin coding DNA sequence (CDS; size: 11.1 Kb).  
In this study we validated a novel stem cell-based non-viral gene therapy 
approach for DMD with the use of piggyBac (PB) transposons. These plasmid-
based non-viral vectors are able to stably integrate the gene of interest into the 
genome of the target cells leading to its sustained expression. Moreover, the 
large cargo capacity of these vectors could overcome one of the main 
bottlenecks in the field enabling gene therapy with full-length instead of truncated 
dystrophin. We have therefore generated PB transposons coding for either full-
length or truncated versions of the human dystrophin CDS. We demonstrated 
that this system enables stable non-viral gene delivery, with sustained 
expression of both full-length and truncated versions of dystrophin into murine 
myoblasts. We subsequently transferred PB transposons containing the full-
length human dystrophin CDS into dystrophic mesoangioblasts (MABs). These 
myogenic vessel associated stem/progenitor cells are capable of crossing the 
vessels and contribute to the regeneration of the dystrophic muscles upon intra-
arterial transplantation. The use of MABs has resulted to be relatively safe in a 
recently completed phase I/II clinical trial based on intra-arterial infusions at 
escalating doses of HLA-matched donor-derived MABs in DMD patients under 
immunosuppressive regimen (EudraCTno. 2011-000176-33). In our study, MABs 
were isolated from the muscles of a large animal model for DMD, the Golden 
Retriever muscular dystrophy (GRMD) dog. The genetically corrected GRMD 
MABs showed stable transposition and expression of the full-length human 
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dystrophin. Since MABs have a limited proliferative capacity, we have also 
investigated the possible use of MABs generated from induced pluripotent stem 
cells (iPSCs) of patients suffering from DMD, as an alternative (designated as 
human iPSC-derived mesoangioblast-like cells or HIDEMs). These cells can be 
expanded in culture to obtain a potentially unlimited supply of myogenic 
progenitors. HIDEMs derived from patients affected by DMD were then 
genetically corrected with PB transposons resulting in stable expression of the 
full-length human dystrophin CDS. These cells successfully engrafted into the 
muscles of immunodeficient/dystrophic mice (scid/mdx) leading to the in vivo 
expression of the PB-mediated full-length human dystrophin in the myofiber 
membrane. 
Taken together, these results showed for the first time the validity of a 
non-viral gene transfer approach based on PB transposons that allows for the 
sustained expression of the full-length human dystrophin in dystrophic MABs and 
DMD patient-specific iPSC-derived MABs. This study paves the way towards a 
novel stem/progenitor cell-based non-viral gene therapy for the treatment of DMD 
exploiting the potential of PB transposons to deliver large therapeutic genes. 
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Samenvatting 
Duchenne spierdystrofie (DMD) is een genetische aandoening, die gekenmerkt 
wordt door mutaties in het dystrofine gen. Hierdoor ontbreekt het dystrofine eiwit 
in de membranen van de spiervezels in de getroffen patiënten. Dit leidt tot 
degeneratie van spiervezels en progressief spierverlies, uiteindelijk resulterend in 
aanzienlijke morbiditeit en mortaliteit. Momenteel is er geen behandeling 
beschikbaar die de ziekteprogressie voorkomt of om kan keren. Genetisch 
gecorrigeerde stam/progenitor cellen kunnen mogelijk een effectieve 
behandeling bieden. De veelgebruikte virale vector technologiën  kunnen echter 
niet toegepast worden wegens de grootte van de complete dystrofine-coderende 
DNA sequentie (CDS; groote: 11.1 Kb), waardoor er geen efficiënte 
genoverdracht plaatsvindt.   
 In deze studie valideerden we een nieuwe stamcel-gebaseerde niet-virale 
gentherapie aanpak voor DMD, met behulp van piggyBac (PB) transposons. 
Deze plasmide-gebaseerde niet-virale vectoren kunnen het betreffende gen 
stabiel integreren in het genoom van de target cellen en zo voor een langdurige 
expressie zorgen. Bovendien kan de relatief grote cargo-capaciteit van deze 
vectoren een mogelijke beperking van gentherapie met virale vectoren omzeilen. 
Daarom hebben we PB transposons gegenereerd die coderen voor de volledige 
en de getrunceerde versie van de humane dystrofine CDS. We hebben 
aangetoond dat dit systeem stabiele niet-virale genaflevering mogelijk maakt, 
met aanhoudende expressie van zowel de intacte als de getrunceerde versies 
van dystrofine in muis myoblasten. Vervolgens hebben we de PB transposons, 
met daarin de volledige dystrofine CDS, getransfecteerd in dystrofische 
mesoangioblasten (MABs). Deze stam/progenitor cellen geassocieerd met 
myogene bloedvaten zijn in staat om bloedvaten te doorkruisen en bij te dragen 
tot  de regeneratie van de dystrofische spieren na intra-arteriële transplantatie. 
Het gebruik van MABs is relatief veilig, zoals aangetoond in een recent 
afgeronde fase I/II klinische studie, met intra-arteriële infusies van toenemende 
dosissen van HLA-gematchte donor-afgeleide MABs in DMD patiënten die met 
immunosuppressiva  werden behandeld  (EudraCTno. 2011-000176-33). In onze 
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studie werden MABs geïsoleerd uit de spieren van een groot diermodel voor 
DMD, het Golden Retriever musculaire dystrofie (GRMD) hondemodel. De 
genetisch gecorrigeerde GRMD MABs vertoonden stabiele transpositie en 
expressie van de intacte humane dystrofine CDS. Om de beperkte 
celdelingscapaciteit van MABs te omzeilen,  hebben we ook de mogelijkheid 
onderzocht om gebruik te maken van MABs gegenereerd uit geïnduceerde 
pluripotente stam cellen (iPSCs), namelijk humane iPSC-afgeleide 
mesangioblast-achtige cellen (HIDEMs). Deze cellen kunnen geëxpandeerd 
worden in cultuur, om zo een potentieel ongelimiteerde voorraad van myogene 
progenitoren te bekomen. HIDEMs afkomstig van patiënten getroffen door DMD 
werden genetisch gecorrigeerd met PB transposons met de intacte humane 
dystofine CDS wat tot stabiele expressie van het dystrofine eiwit leidde. Deze 
cellen konden succesvol getransplanteerd worden in de spieren van 
immunodeficiënte/dystrofische muizen (scid/mdx) en leidden tot de in vivo 
expressie van de PB-gemedieerde volledige humane dystrofine eiwit in het 
spiervezelmembraan.  
 Samengenomen tonen deze resultaten voor het eerst de validiteit van een 
niet-virale gentransfer aanpak, gebaseerd op PB transposons, die zorgt voor 
stabiele expressie van het intacte humane dystrofine in dystrofische MABs en 
DMD patiënt-specifieke iPSC-afgeleide MABs. Deze studie opent nieuwe 
mogelijkheden voor de behandeling van DMD op basis van niet-virale 
gentherapie met stam/progenitor cellen, waarbij het potentieel van PB 
transposons geëxploiteerd wordt om relatief grote therapeutische genen te 
transfecteren. 
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PBS: Phosphate-buffered saline 
PCR: Polymerase chain reaction 
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1. Introduction 
1.1. Duchenne muscular dystrophy 
Duchenne muscular dystrophy (DMD; OMIM #310200) is amongst the most 
severe forms of muscular dystrophies, a heterogeneous group of inheritable 
pathologies characterized by the progressive weakening and degeneration of the 
skeletal muscle tissue (Mercuri and Muntoni, 2013; Emery, 2002). DMD is an X-
linked disease affecting up to 1 in 5000 male newborns (Mendell and Lloyd-
Puryear, 2013). It was first described by the English physician Edward Meryon in 
1851 (Emery, 1993), who indicated its familial inheritance and significantly higher 
incidence in male subjects. This pathology owes its name to the French 
neurologist Duchenne de Boulogne who, a few years later, extensively detailed 
its symptoms, clinical features and pathological progression (Parent, 2005). 
Patients suffering from DMD generally experience difficulties running, standing 
and climbing stairs in early childhood. In this form of muscular dystrophy, muscle 
weakness is mainly proximal and progressive (Gower’s sign). For this reason 
most of the patients are confined to a wheelchair by 12 years of age. The 
continuous impairment of the daily functional abilities drastically affects the 
patients’ quality of life and causes a shortened life expectancy, mainly due to 
cardiac and respiratory complications. 
DMD and its milder form Becker muscular dystrophy (BMD; OMIM #300376) are 
caused by mutations in the dystrophin gene (Hoffman et al., 1987). This is the 
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largest gene found in nature with a sequence of 2.4 Megabases (Mb) composed 
by 79 exons and coding for the dystrophin protein (427 kDa). This is a large 
protein that localizes in proximity of the myofiber membrane and is the main 
component of dystrophin-associated protein complex (DAPC; Figure 1; 
(McGreevy et al., 2015; Ervasti, 2007; Blake et al., 2002)). The complex 
functions as a mechanical link between the cytoskeletal components (actin and 
microtubules) and laminin in the extracellular matrix. Dystrophin presence is 
crucially required to give the stability of the complex and consequently to support 
the structural integrity of the myofibers (Petrof et al., 1993).  
 
 
Figure 1. Schematic representation of the dystrophin and the DAPC. Dystrophin 
contains N-terminal (NT), middle rod, cysteine-rich (CR) and C-terminal (CT) domains. 
The middle rod domain is composed of 24 spectrin-like repeats and four hinges (H1, H2, 
H3 and H4). Dystrophin has two actin-binding domains located at NT and repeats 11-15, 
respectively. Repeats 1-3 interact with the lipid bilayer. Repeats 16 and 17 form the 
neuronal nitric oxide synthase (nNOS)-binding domain. Dystrophin interacts with 
microtubules through repeats 20-23. Part of H4 and the CR domain bind to the β-
dystroglycan (βDG). The CT domain of dystrophin interacts with syntrophin (Syn) and 
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dystrobrevin (Dbr). Dystrophin links components of the cytoskeleton (actin and 
microtubule) to laminin in the extracellular matrix. Adapted from (McGreevy et al., 2015). 
 
In DMD patients, lack of dystrophin makes the sarcolemma membrane 
vulnerable to damage, in response to muscle contractions. This leads to 
continuous cycles of degeneration and regeneration. Initially, resident stem cells 
increase their number, aiming to regenerate the afflicted myofibers (Kuang et al., 
2008). However, this compensatory mechanism fails to sustain long-term tissue 
regeneration, producing damaged myofibers and necrotic tissue. This results in a 
chronic inflammation characterized by an increased number of resident 
monocytes combined with fibrotic and adipose infiltration that cause a permanent 
loss of muscular mass and function (Mann et al., 2011). The increased number of 
cell divisions causes a deleterious premature exhaustion of the stem cell pool to 
the extent that the regenerative process becomes impaired (Sacco et al., 2010; 
Decary et al., 2000). Nevertheless, a recent study provides new insights into the 
role of dystrophin, suggesting that in DMD it is not the depletion of muscle stem 
cells per se, but rather the absence of dystrophin that causes a dysfunction of 
these cells and consequently an impaired regeneration, due to a poor 
differentiation in myocytes (Dumont et al., 2015).  
A first clinical diagnosis of DMD is based on the presence of impaired muscle 
function, delayed speech and elevated levels of muscle enzymes in the serum, 
like creatine kinase (Bushby et al., 2010a). The validation of the clinical diagnosis 
occurs via molecular biology techniques, including genetic analysis on the DMD 
gene, immunocytochemistry and Western blot analysis (Aartsma-Rus et al., 
2016). Most of the DMD patients show deletions (∼68%) or duplications (∼11%) 
of one or several exons, and the remaining ∼20% of patients is affected by small 
mutations. While the deletions are concentrated between exons 45–55, 
duplications occur more frequently between exons 2–10 (Bladen et al., 2015). In 
Figure 2, the functional domains of the dystrophin protein are indicated on the 
correspondent coding exons of the dystrophin gene (McGreevy et al., 2015). 
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In DMD, mutations that disrupt the reading frame or generate a premature stop 
codon lead to loss of protein function. However, revertant fibers expressing the 
dystrophin are found in DMD patients as a consequence of somatic mutations 
which restore the frameshift of the original mutations in the dystrophin gene 
(Klein et al., 1992). In BMD, mutations that maintain the open reading frame 
allow the production of a reduced amount or abnormal size of dystrophin proteins 
that are partially functional. Consequently, BMD patients show a milder 
phenotype compared to DMD patients, due to a later onset of the disease and a 
slower degenerative progression.  
 
 
Figure 2. Schematic representation of the dystrophin exons and the 
corresponding functional domains. Most of the DMD mutations in patients are 
deletions concentrated between exons 45–55 or duplications that occur more frequently 
between exons 2–10. In the schematic representation of the dystrophin coding exons, 
the corresponding functional domains of the dystrophin protein are also reported. The 
features are indicated with the same terminology as that used in Figure 1. AB1 and AB2 
correspond to the actin-binding domain 1 and 2. Adapted from (McGreevy et al., 2015). 
 
1.2. Therapeutic approaches to treat Duchenne muscular 
dystrophy 
In the last two decades, the life expectancy and the quality-of-life of DMD 
patients have significantly improved thanks to treatment with anti-inflammatory 
and immunosuppressive drugs and an advanced standard of care (Mercuri and 
Muntoni, 2015; Serra et al., 2012; Bushby et al., 2010a, 2010b). Nevertheless, to 
date no definitive treatment is available for DMD patients. 
The design of novel therapeutic approaches to treat patients affected by DMD 
needs to take into account the various aspects related to the nature of the 
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disease (Boisgerault and Mingozzi, 2015; Al-Zaidy et al., 2014; Maffioletti et al., 
2014; Mercuri and Muntoni, 2013; Tedesco and Cossu, 2012; Arechavala-
Gomeza et al., 2010). An effective therapeutic strategy for DMD should ideally 
target different muscle districts, alleviate respiratory and cardiac complications, 
prevent or at least limit fibrotic tissue accumulation, prevent or suppress a 
potential immune response to dystrophin and have a sustainable long-term 
effect.  
 
Numerous animal models of DMD, both naturally occurring and generated in 
laboratory, are available to study the pathogenic mechanisms of this muscle 
disorder and validate possible therapies for treating DMD, reviewed in 
(McGreevy et al., 2015). The most commonly used animal model is the mdx 
mouse with a nonsense point mutation C->T in exon 23 of the dystrophin gene 
that results in the absence of the full-length dystrophin expression (Sicinski et al., 
1989). However, this model shows some limitations, such the development of 
dystrophin-positive revertant fibers and a mild clinical phenotype that could 
impair the assessment of a therapeutic approach based on the restoration of the 
dystrophin expression. Moreover, the lifespan of mdx mice is reduced only by 
~25% in contrast to the lifespan of DMD patients that is reduced by ~75% 
(Chamberlain et al., 2007). Although the development of mouse strains with a 
more severe dystrophic phenotype, however the body size and immune 
response of these animal models remain significantly different compared to the 
human ones. To overcome these limitations, canine models for DMD have been 
established, such as the golden retriever muscular dystrophy (GRMD) dog 
(Cooper et al., 1988). This large size animal model carries a point mutation A->G 
in the intron 6 of the dystrophin gene that causes the skipping of exon 7 and a 
premature termination of translation. The severe phenotype of the GRMD dog 
resembles the clinical features of DMD patients with a lifespan reduced by ~75%. 
Moreover this animal model simulates  the immune response observed in 
individuals affected by DMD thus representing an excellent model for this muscle 
disorder (Duan, 2015). 
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The complexity of this scenario has led to a number of different therapies for 
DMD currently under investigation, in preclinical and clinical studies. These can 
be classified in three main categories: 
- Pharmacological therapy 
- Cell therapy 
- Gene therapy 
 
1.2.1. Pharmacological therapy 
Various pharmacological approaches have been used to directly restore the 
dystrophin expression in DMD patients. Gentamicin and Ataluren (PTC124) have 
been shown to induce a ribosomal read-through of the premature stop mutations 
in the defective gene, leading to the restored production of a functional full-length 
dystrophin (Welch et al., 2007; Barton-Davis et al., 1999). However, recent 
clinical trials based on gentamicin have demonstrated modest beneficial effects 
accompanied by significant side effects (Malik et al., 2010). Recently, hybrid 
liposomes-based drug-delivery systems have been developed to reduce the 
toxicity of gentamicin and increase its efficiency (Yukihara et al., 2011). On the 
other hand, encouraging results were observed in a Phase II clinical trial with 
Ataluren, where this drug seemed beneficial at low dose (Finkel et al., 2013). 
This led to a Phase III clinical trial aimed to assess the long-term safety and 
efficacy (Bushby et al., 2014). The European Medicines Agency granted 
conditional marketing authorization for this drug (Traslarna), making it the first 
drug approved for the treatment of DMD patients (Ryan, 2014).  
Alternative pharmacological approaches are being explored that are based on 
the induction of a functional compensatory system. In particular, small molecule 
drugs can stimulate the transcription and increase the protein levels of the 
utrophin, the autosomal paralogue of the dystrophin (Tinsley et al., 2011; Tinsley 
and Davies, 1993). The increased levels of utrophin restore the assembly of the 
DAPC at the level of the sarcolemma and ameliorate the dystrophic phenotype. 
Since utrophin is naturally expressed in DMD patients and is not affected by 
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mutations in the dystrophin gene, no immunological response against this protein 
is expected as the immune system is tolerant to this “self” protein. This is in 
contrast with the induction of immune responses upon de novo expression of a 
functional dystrophin after gene therapy and/or after naturally occurring somatic 
reversion mutations (Mendell et al., 2010). Moreover this strategy is potentially 
effective for all DMD patients, regardless of the underlying gene defect. The 
utrophin modulators have been recently tested in a Phase I clinical trial to 
investigate safety, tolerability and pharmacokinetics, with encouraging results 
(Tinsley et al., 2015). However, compensatory methods do not correct the 
genetic defect that causes DMD.  
Several other drugs are undergoing preclinical and clinical evaluation aiming to 
treat dystrophic patients such as insulin-like growth factor-I (IGF-I; (Barton et al., 
2002)), nitric oxide-releasing drugs (Brunelli et al., 2007), myostatin inhibitors 
(Wagner et al., 2008), anti-inflammatory molecules (Serra et al., 2012), 
phosphodiesterase type 5 (PDE5) inhibitors aiming to reduce muscle ischemia 
(Nelson et al., 2014) and more recently anti-oxidant drugs (Buyse et al., 2015). 
The use of pharmacological methods is limited by the continuous need for drug 
administration and the potential undesirable toxic effects at therapeutic doses of 
a given drug. 
 
1.2.2. Cell therapy 
Cell therapy to treat muscular dystrophies is based on the transplantation of 
allogeneic or genetically corrected autologous stem/progenitor cells aiming to 
provide a correct functional copy of the mutated gene.  
Satellite cells are the resident stem cells of skeletal muscle. These cells are 
considered the main player in skeletal muscle development, postnatal growth 
and regeneration of the damaged myofibers (Relaix and Zammit, 2012). First 
observed via transmission electron microscopy by Alexander Mauro in 1961, 
satellite cells are located in a peripheral position to the myofibers, with their niche 
underneath the myofiber basal lamina (Mauro, 1961). In the adult, satellite cells 
are mitotically quiescent and can be identified by the expression of the 
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transcription factor paired box 7 (Pax7, (Zammit et al., 2006)). In response to 
muscle injury, they become activated and asymmetric cell division takes place. 
These divisions generate committed cells, called myoblasts, and satellite cells 
that replenish the pool of quiescent stem cells (Rocheteau et al., 2012; Le Grand 
et al., 2009; Kuang et al., 2007; Shinin et al., 2006). Myoblasts can be identified 
for their positivity for both the markers Pax7 and myogenic differentiation 1 
(MyoD). However, MyoD positivity is still debated as a defining criterium to 
identify activated satellite cells/myoblasts. Alternatively, a more relevant role for 
myogenic factor 5 (Myf5) has been suggested (Kuang et al., 2008; Rudnicki et 
al., 2008).  
Because of their ability in regenerating skeletal muscle, myoblasts were the first 
cell type utilized for cell transplantation. After promising preclinical results 
obtained in dystrophic mdx mice (Partridge et al., 1989), several clinical trials 
have been carried out based on allogeneic myoblast transplantation in DMD 
patients. These trials showed very limited efficacy, probably as a result of poor 
survival, immune rejection and/or limited migration of transplanted cells (Tedesco 
and Cossu, 2012; Negroni et al., 2011). Consequently, further studies have been 
done to improve clinical trial protocols for allogeneic myoblast transplantation in 
DMD patients, implementing immunosuppressive regimens to enhance 
engraftment efficiency and performing high-density injections to treat large 
volumes of muscles (ClinicalTrials.gov NCT02196467 (Skuk and Tremblay, 
2011; Skuk et al., 2007)). Nevertheless, this approach was not efficient for the 
treatment of DMD, where the body-wide treatment of the muscles would be 
required. A different scenario was observed in a phase I/IIa clinical trial for 
patients affected by oculopharyngeal muscular dystrophy (OPMD), treated with 
autologous intramuscular transplantation of myoblasts (ClinicalTrials.gov 
NCT00773227, (Périé et al., 2014)). In this particular pathology, caused by 
heterozygous mutation in the gene coding for polyadenylate-binding protein 
nuclear 1 (PABPN1), small muscles of the face and the neck are specifically 
affected by degeneration. Autologous myoblasts isolated from unaffected limb 
muscles were transplanted in the dystrophic pharyngeal muscles, leading to 
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clinical benefits to the patients with no adverse effects. These encouraging 
results support the use of autologous myoblast transplantation as a therapeutic 
strategy for limited muscle districts. 
An ideal route to deliver cells through all the muscle districts of the body in DMD 
patients would be the circulatory system. Intravenous injection would be the 
simplest approach. However, cells administered trough this route will be trapped 
in the filter organs before reaching the skeletal muscles (Sharma et al., 2014; 
Schrepfer et al., 2007). Alternatively, intra-arterial administration has been 
considered to target the muscle tissue. Myoblasts are unable to cross the blood 
vessel wall upon systemic delivery, thus limiting their use for the treatment of 
patients affected with systemic myopathies such as DMD (Dellavalle et al., 2007; 
Sampaolesi et al., 2006).  
To overcome these limitations, other cell populations isolated from various 
tissues and capable of contributing to muscle regeneration have been 
investigated for the development of novel cell therapy strategies to treat DMD, 
such as mesoangioblasts (MABs; Table 1; (Costamagna et al., 2015; Benedetti 
et al., 2013). The use of these adult stem cells in clinical trials for DMD has 
proven relatively safe, though efficicacy could still be improved (Cossu et al., 
2015; Torrente et al., 2007).  
However, the proliferative potential of these primary cells is not unlimited, thus 
affecting the large-scale production required to treat all of the skeletal muscles of 
patients with DMD (Holliday, 2014). Moreover, depletion or dysfunction of 
myogenic progenitors has been reported in different forms of muscular 
dystrophy, making their isolation more complex (Dumont et al., 2015; 
Kudryashova et al., 2012; Tedesco et al., 2012; Cassano et al., 2011; Sacco et 
al., 2010). This would affect also the investigation on these muscle disorders, 
being the patient-derived primary cells with myogenic potential considered the 
most common cell sources for assessing the disease phenotypes in in vitro 
studies. 
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To overcome these limitations, different protocols have been recently developed 
to generate transplantable skeletal muscle progenitors from pluripotent stem cells 
(Table 2 and Table 3; (Loperfido et al., 2015a)). These cells have the potential to 
be expanded indefinitely, allowing the production of the large numbers of cells 
required for cell-based therapies of skeletal muscle disorders. Notably, the 
possibility to derive patient-specific induced pluripotent stem cells (iPSCs) in 
combination with the current development of gene modification methods provides 
an attractive alternative for the treatment of genetic diseases by ex vivo gene 
therapy, moving closer to the prospect of an autologous and personalized cell 
therapy (Figure 3; (Loperfido et al., 2015a)). Moreover, skeletal muscle 
progenitors derived from patient-specific iPSCs can be used as an in vitro model 
to recapitulate the primary pathology, such as DMD, and for drug screening 
studies (Shoji et al., 2015; Abujarour et al., 2014). 
Nevertheless, further studies are needed to ultimate the clinical translation.  
 
In light of the results reported in this thesis, the next paragraphs will focus on 
MABs, vessel-associated progenitor cells, and their iPSC-derived counterpart, 
named HIDEMs (Human iPSC-derived mesoangioblast-like cells).  
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Figure 3. Potential autologous iPSC-based ex vivo gene therapies for muscle 
disorders. Cells from easily accessible sources can be obtained from patients affected 
by muscular dystrophies and reprogrammed into iPSCs by addition of reprogramming 
factors. The resulting iPSCs can then be committed into a potentially unlimited number 
of myogenic cells. Adapted from (Loperfido et al., 2015a) 
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1.2.2.1. Mesoangioblasts 
Initially described by Bianco and Cossu’s groups, mesoangioblasts (MABs) are 
defined as the in vitro counterpart of post-natal skeletal muscle pericytes (Cossu 
and Bianco, 2003). Isolated from the mouse embryonic dorsal aorta, these cells 
were assigned to the perivascular lineage and showed variable level of 
expression of the markers alkaline phosphatase (AP), fetal liver kinase 1 (Flk-1), 
smooth muscle actin (SMA), c-kit (CD117) and CD34. MABs are able to 
contribute to different mesodermal tissues in vivo, including skeletal muscle 
(Minasi et al., 2002). These cells have been subsequently isolated from adult 
mouse, dog and human skeletal muscle biopsies (Dellavalle et al., 2007; 
Tonlorenzi et al., 2007; Sampaolesi et al., 2006, 2003). More recently, lineage 
tracing experiments have shown that AP-positive pericytes and their progeny 
contribute to postnatal muscle development and are able to give rise to Pax7 
positive satellite cells during growth and skeletal muscle regeneration (Dellavalle 
et al., 2011; Tedesco et al., 2011). Similarly to what was observed with 
mesenchymal stem cells (English and Mahon, 2011), adult mesoangioblasts 
have been reported to have an immunomodulatory potential, inhibiting T cell 
proliferation (English et al., 2013). Moreover, allogeneic mesoangioblasts can 
elicit an immune response only in presence of inflammatory cytokines (Noviello 
et al., 2014). 
Since their discovery, MABs have been considered appealing candidate cells for 
cell therapy of muscular dystrophies as an alternative to myoblasts (Sampaolesi 
et al., 2005). In contrast to myoblasts, MABs have been shown able to cross the 
vessel wall upon intra-arterial delivery and colonize the downstream muscles, 
which is a major advantage for cell therapy (Dellavalle et al., 2007; Sampaolesi 
et al., 2006; Palumbo et al., 2004; Sampaolesi et al., 2003). Here, MABs actively 
contribute to muscle regeneration, thus leading to amelioration of the dystrophic 
phenotype of murine and canine models of muscular dystrophy (Sampaolesi et 
al., 2006, 2003). Moreover, MABs can be easily manipulated with viral and non-
viral vectors, making them suitable for gene and cell therapy approaches 
(Tedesco et al., 2011; Dellavalle et al., 2007; Sampaolesi et al., 2006). Based 
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upon these findings, a series of studies investigated the possible applications of 
MABs to correct aged dystrophic muscles (Gargioli et al., 2008), cardiac defects 
(Galli et al., 2005) and  different forms of muscular dystrophies (Domi et al., 
2015; Díaz-Manera et al., 2010).  
 
The encouraging results coming from these pre-clinical studies have led to a first-
in-human phase I/II clinical trial based on intra-arterial transplantation of 
allogeneic MABs in five DMD patients, under immunosuppressive regimen 
(EudraCT N°2011–000176–33, (Cossu et al., 2015)). This trial, completed in 
2015, met its primary endpoint providing insightful information on the safety of 
these cells to treat DMD patients. The administration at escalating doses of HLA-
matched donor MABs in the limb arteries of the patients was possible without 
adverse events related to the procedure itself. Though the overall efficacy could 
still be improved, it sets the stage for future trials that may require enrollment of 
younger patients with less advanced muscle disease and/or increasing the MAB 
dose. Moreover, gene therapy approaches could be exploited to further amplify 
the therapeutic effect using genetically modified autologous MABs that over-
express dystrophin upon myogenic differentiation. The use of such autologous 
MABs may obviate the need for immune suppression, in contrast to when 
allogeneic MABs are employed. Ultimately, whether these intrinsic 
immunosuppressive properties of MABs would suffice to prevent a dystrophin-
specific immune response after transplantation of genetically modified, 
dystrophin-expressing MABs remains to be addressed in future clinical studies. 
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Cell type Tissue of 
origin 
Delivery Animal model (disease) Clinical Trials 
Satellite cells and 
myoblasts  
Skeletal 
muscle 
Local mdx mice (DMD) (Partridge et al., 1989); 
mdx nu/nu mice (DMD) (Montarras et al., 
2005) 
Phase I/II: Recruiting 
(DMD)* (Skuk and 
Tremblay, 2011); 
Phase I/IIa: 
completed (OPMD) 
(Périé et al., 2014) 
Pericytes and 
Mesoangioblasts 
Vessels /  
Skeletal 
muscle 
Systemic 
/ Local 
scid/mdx mice (DMD) (Dellavalle et al., 
2007; Tedesco et al., 2011);                                  
sgca-null mice (LMG2D)  (Gargioli et al., 
2008; Sampaolesi et al., 2003); scid/BIAJ 
mice (LMG2B) (Diaz-Manera et al., 
2010);  GRMD dogs (DMD) (Sampaolesi 
et al., 2006) 
Phase I/II: completed 
(DMD) (Cossu et al., 
2015) 
Muscle derived 
stem cells 
Skeletal 
muscle 
Systemic 
/ Local 
mdx mice (DMD) (Cao et al., 2003; Qu-
Petersen et al., 2002; Gussoni et al., 1999); 
mdx nude mice (DMD) (Meng et al., 2016; 
Meng et al. 2011); GRMD dogs (DMD) 
(Rouger et al., 2011)  
N/A 
CD133 positive 
cells 
Blood / 
skeletal 
muscle 
Systemic 
/ Local 
scid/mdx mice (DMD)(Benchaouir et al., 
2007; Torrente et al., 2004); scid dysferlin 
null mice (MM) (Meregalli et al., 2013) 
Phase I: completed 
(DMD) (Torrente et 
al., 2007); 
Phase II: Recruiting 
(DMD) 
Pw1 positive 
Interstitial cells 
Skeletal 
muscle  
Local Injured nude mice (Mitchell et al., 2010) N/A 
Mesenchymal 
stem cells 
Bone 
marrow / 
vessels** 
Systemic 
/ Local 
Injured rats and mdx nude mice (DMD) 
(Dezawa et al., 2005); injured NOD/scid 
and scid/mdx mice (Crisan et al., 2008); 
injured Rag2+ϒc+/C5 mice (Meng et al., 
2010); injured nude mice (De Bari et al., 
2003); mdx mice (DMD)  (Gang et al., 
2009; Wernig et al., 2005; De Bari et al., 
2003) 
N/A 
Hematopoietic 
stem cells 
Bone 
marrow / 
blood 
Systemic  
/ Local 
mdx mice (DMD) (Gussoni et al., 1999); 
mdx4cv mice (Ferrari et al., 2001); injured 
scid/beige mice (Ferrari et al., 1998);                               
injured mice (Corbel et al., 2003) 
N/A 
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Amniotic fluid 
stem cells 
Amniotic 
fluid 
Systemic HSA-Cre, SmnF7/F7 mice (Piccoli et al., 
2012) 
N/A 
 
Table 1. Summary of cell populations used in preclinical and clinical studies to 
treat muscular dystrophies. * Past clinical trials on DMD have been reviewed in 
(Tedesco and Cossu, 2012). ** Cells have been isolated from other connective tissues 
that are also referred to as MSCs. This is in agreement with the criteria proposed by the 
Society for Cell Therapy for defining MSCs (Dominici et al., 2006). Adapted from 
(Benedetti et al., 2013). 
 
1.2.2.2. Human induced pluripotent stem cell-derived 
mesoangioblast-like cells 
In order to overcome the limited expansion potential of primary cells and their 
poor availability observed in the biopsies of the patients with limb-girdle muscular 
dystrophies 2D (LGMD2D), a method to derive MAB-like cells from human and 
mouse iPSCs was developed (Tedesco et al., 2012) that was further extended 
and optimized as a joint effort between Tedesco’s group and ours (Maffioletti et 
al., 2015). In particular, this methodology was adapted to human embryonic stem 
cells (ESCs) and iPSCs cultured in feeder-free conditions and was validated 
based on iPSCs derived from several distinct genetic muscle disorders, including 
DMD.  
Starting from a pluripotent stem cell culture, this optimized and novel technique 
allows robust differentiation towards the mesodermal lineage. The protocol 
entails a series of culture passages at different cell densities: in a first phase 
(early commitment) gently dissociated pluripotent cells are cultured at high 
density on matrigel coated dishes; the following steps (intermediate and late 
commitment) allow cells adaptation to a lower density, enzymatic dissociation 
and culture in proliferation media normally utilized to expand primary human 
MABs. Cells obtained with this protocol resemble MABs on the basis of their 
morphological characteristics, cell surface markers and gene expression profile 
and are characterized by a robust expansion potential. Terminal myogenic 
differentiation is then triggered upon tamoxifen-mediated conditional 
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overexpression of the transcription factor MyoD fused with the estrogen receptor 
for nuclear translocation (MyoD-ER(T), (Tedesco et al., 2012; Kimura et al., 
2010)). This method allowed the derivation of the so-called human iPSC-derived 
mesoangioblast-like cells (HIDEMs) from healthy donors, LGMD2D patients and, 
relevant for this work, from DMD patients. LGMD2D HIDEMs were genetically 
corrected with a lentiviral vector coding for the human α-sarcoglycan gene 
(whose mutations cause LGMD2D) under a muscle specific promoter and then 
also transduced with another lentiviral vector coding for the MyoD-ER(T) 
transgene as a myogenic differentiation switch, as described above. Genetically 
corrected LGMD2D HIDEMs were successfully transplanted intramuscularly and 
intra-arterially into α -sarcoglycan-null immunodeficient (Sgca-null/scid/beige) 
mice, a preclinical model of LGDM2D, and produced α-sarcoglycan-positive 
muscle fibres that were detectable one-month post transplantation. 
Consequently, de novo expression of the missing α-sarcoglycan led to the 
reconstitution of the dystrophin-associated protein complex in host myofibers. 
Similarly, species-specific transplantation of mouse iPS cell-derived MAB-like 
progenitors in Sgca-null/scid/beige mice led to engraftment of large areas of host 
muscle, re-establishment of muscle pericytes in vivo and functional amelioration 
of the dystrophic phenotype. This proof of concept study established the validity 
of an autologous gene therapy approach for the treatment of LGMD2D, and 
possibly other forms of muscular dystrophy, based upon transplantable iPSC-
derived myogenic cells. Indeed, the same protocol allowed the generation of 
HIDEMs also from DMD iPSCs, which were genetically corrected with the DYS-
HAC (Loperfido et al., 2015a; Gerli et al., 2014; Tedesco et al., 2012) (see 
below). Interestingly, analysis of the interaction between HIDEMs and immune 
cells suggests a reduced risk of evoking potential immune responses. Indeed, 
HIDEMs suppress T cell proliferation through IDO and PGE-2 dependent 
pathways, consistent with the results from tissue-derived mesoangioblasts 
(Loperfido et al., 2015a; English et al., 2013; Li et al., 2013). 
Overall, HIDEMs showed great proliferation potential and a strong myogenic 
differentiation ability. This aspect combined with the availability of patient-specific 
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DMD HIDEMs made these cells an appealing candidate to test the transposon-
based genetic correction strategy investigated in this thesis.  
 
Pluripo
tent 
stem 
cell 
Origin 
Muscle 
differentiation 
method  
Mouse model & 
genetic correction 
In vivo results 
Refs Engraftment/ 
Differentiation 
Systemic 
delivery 
Functional 
test 
ESCs 
mouse 
EB cocultured with 
primary muscle 
cells 
WT cells into mdx 
mouse, no genetic 
correction 
✔  ✗ ✗ 
 Bhagavati 
et al., 
2005 
MyoD integration 
(IND)  
WT cells into mdx 
mouse, no genetic 
correction 
✔  ✗ ✗ 
Ozasa et 
al., 2007 
Pax3 integration 
(IND), EB, PDGF- 
αR+ Flk-1- cell 
sorting 
WT cells into mdx 
mouse, no genetic 
correction 
✔  ✔  ✔  
Darabi et 
al., 2008 
Pax3 or Pax7 
integration (IND), 
EB, PDGF- αR+ 
Flk-1- cell sorting 
WT cells into mdx 
mouse, no genetic 
correction 
✔  ✔  ✔  
Darabi et 
al., 2011 
mesodermal 
commitment, 
PDGF- αR+ cell 
sorting 
WT cells into 
immunodeficient 
mouse, no genetic 
correction 
✔  ✗ ✗ 
Sakurai et 
al., 2008 
EB and SM/C-2.6 
cell sorting  
WT cells into mdx 
mouse, no genetic 
correction 
✔  ✗ ✗ 
Chang et 
al., 2009 
EB, GSK-3 
inhibitor 
(CHIR99021), 
bFGF, N2 
NA ✗ ✗ ✗ 
Shelton et 
al., 2014 
Myf5 integration 
(IND), EB 
NA ✗ ✗ ✗ 
Iacovino 
et al., 
2011 
human 
mesenchymal 
commitment, 
CD73+ and NCAM+ 
cell sorting 
HD into 
immunodeficient 
mouse, no genetic 
correction 
✔  ✗ ✗ 
Barberi et 
al., 2007 
Pax7 LV integration 
(IND), EB, 
purification by cell 
sorting 
HD into 
immunodeficient/mdx 
mouse, no genetic 
correction 
✔  ✗ ✔  
Darabi et 
al., 2012 
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EB, mesenchymal 
commitment 
HD into 
immunodeficient 
mouse, no genetic 
correction 
✔  ✗ ✗ 
Awaya et 
al., 2012 
myogenic medium, 
MyoD AAV 
Dys null cells into 
immunodeficient/mdx 
mouse, no genetic 
correction 
✔  ✗ ✗ 
Goudeneg
e et al., 
2012 
BAF60C and MyoD 
LV integration 
NA ✗ ✗ ✗ 
Albini et 
al., 2013 
GSK-3 inhibitor 
(CHIR99021), 
bFGF, N2 
NA ✗ ✗ ✗ 
Shelton et 
al., 2014 
Myf5 integration 
(IND), EB 
NA ✗ ✗ ✗ 
Iacovino 
et al., 
2011 
mesodermal 
commitment, 
MyoD-ER(T) 
LV integration 
(IND) 
NA ✗ ✗ ✗ 
Maffioletti 
et al., 
2015 
 
Table 2. Summary of muscle differentiation protocols from ESCs and genetic 
correction. NA: Not assessed (no disease, no genetic correction, in vitro only); ✔ 
Performed; ✗ Not performed. Adapted from (Loperfido et al., 2015a). 
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Pluripo
tent 
stem 
cells 
Origin 
Muscle 
differentiation 
method  
Mouse model & 
genetic correction 
In vivo results 
Refs Engraftment/ 
Differentiation 
Systemic 
delivery 
Functional 
test 
iPSCs 
mouse 
Pax7 integration 
(IND), EB, PDGF-
αR+ Flk-1- cell 
sorting 
WT cells into mdx 
mouse, no genetic 
correction 
✔  ✗ ✔  
Darabi et 
al., 2011 
Pax3 LV integration 
(IND), EB, PDGF-
αR+ Flk-1- cell 
sorting 
µutrn-SB transposon 
corrected, dys 
null/µutrn positive 
cells into dys null/utrn 
null mouse 
✔  ✔  ✔  
Filareto et 
al., 2013 
mesodermal 
commitment, 
MyoD-ER(T) LV 
integration (IND) 
WT cells into Sgca-
null/immunodeficient 
mouse, no genetic 
correction 
✔  ✔  ✔  
Tedesco 
et al., 
2012; 
Gerli et 
al., 2014 
EB and SM/C-2.6 
cell sorting  
WT cells into mdx 
mouse, no genetic 
correction 
✔  ✗ ✗ 
Mizuno et 
al., 2010 
EB and SM/C-2.6 
cell sorting 
DMD: mdx iPSCs 
with full-length dys 
cDNA into scid/mdx 
✔ ✗ ✗ 
Zhao et 
al., 2014 
Pax3 transposon 
integration and EB 
NA ✗ ✗ ✗ 
Belay et 
al., 2012 
human 
Pax7 LV integration 
(IND), EB, 
purification by cell 
sorting 
HD into 
immunodeficient or 
immunodeficient/mdx 
mouse, no genetic 
correction 
✔  ✗ ✔  
Darabi et 
al., 2012 
EB, mesenchymal 
commitment 
HD into 
immunodeficient 
mouse, no genetic 
correction 
✔  ✗ ✗ 
Awaya et 
al., 2012 
treatment with 
GSK-3 inhibitor 
(CHIR99021) and 
bFGF, sorting for 
AChR+ or 
CXCR4+/C-MET+ 
NA ✗ ✗ ✗ 
Borchin et 
al., 2013 
 52 
EB and treatment 
with GSK-3 
inhibitor (BIO), 
bFGF and forskolin 
HD into 
immunodeficient 
mouse, no genetic 
correction 
✔  ✗ ✗ 
Xu et al., 
2013 
mesodermal 
commitment, 
MyoD-ER(T) LV 
integration (IND) 
LGMD2D: HD and 
Sgca-LV 
corrected,(muscle 
specific promoter) 
cells into Sgca-
null/immunodeficient 
mouse 
✔  ✔  ✗ 
Tedesco 
et al., 
2012; 
Gerli et 
al., 2014; 
Maffiolett
i 2015 
mesodermal 
commitment, 
MyoD-ER(T) LV 
integration (IND) 
DMD: DYS-HAC 
corrected, in vitro only ✗ ✗ ✗ 
Tedesco 
et al., 
2012; 
Maffiolett
i 2015 
myogenic medium, 
MyoD AAV 
DMD cells into 
immunodeficient/mdx 
mouse, no genetic 
correction 
✔  ✗ ✗ 
Goudeneg
e et al., 
2012 
MyoD (IND) PB-
transposon 
integration 
HD cells into 
immunodeficient/DM
D mouse, no genetic 
correction 
✔  ✗ ✗ 
Tanaka et 
al., 2013 
MyoD (IND) PB-
transposon 
integration 
MM: DYSF-PB 
transposon corrected, 
in vitro only 
✗ ✗ ✗ 
Tanaka et 
al., 2013 
MyoD (IND) PB-
transposon 
integration 
CPT II: in vitro only, 
no genetic correction 
✗ ✗ ✗ 
Yasuno et 
al., 2014 
    
MyoD LV 
integration (IND) 
HD, DMD, Becker, in 
vitro only, no genetic 
correction 
✗ ✗ ✗ 
Abujarour 
et al., 
2014 
 
Table 3. Summary of muscle differentiation protocols from iPSCs and genetic 
correction. NA: Not assessed (no disease, no genetic correction, in vitro only); ✔ 
Performed; ✗ Not performed. Adapted from (Loperfido et al., 2015a). 
 
1.2.3. Gene therapy 
Gene therapy offers a unique scenario for the treatment of monogenic disorders. 
The use of advanced technologies tailored to correct the genetic defect 
underlying a disease has recently led to successful clinical trials (Hacein-Bey 
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Abina et al., 2015; Hacein-Bey-Abina et al., 2014; Nathwani et al., 2014; Aiuti et 
al., 2013; Biffi et al., 2013; Cavazzana-Calvo et al., 2010). The expression of the 
missing protein can be restored in the patients by direct correction of the mutated 
gene in the affected tissues (in vivo gene therapy) or alternatively by correction of 
the target cells isolated from the patient and subsequently re-administrated (ex 
vivo gene therapy). Despite early adverse events (Howe et al., 2008; Stein et al., 
2010), the development of efficient, safe, non-immunogenic gene therapy 
procedures leading to long-term therapeutic effects have supported the market 
authorization of the first gene therapy product in the Western world (Glybera, 
(Kastelein et al., 2013)). 
Different in vivo and ex vivo gene therapy strategies have been developed for 
DMD, aiming to restore the expression of the missing protein by modulation of 
the RNA processing (i.e. “exon-skipping”) or by gene repair mechanisms (i.e. 
“gene editing”), or in alternative to replace the defected gene by adding a 
functional copy (i.e. “gene addition” or “gene replacement”)). 
 
1.2.3.1. Exon-skipping 
Exon-skipping is a gene correction approach based on short synthetic fragments 
of nucleic acids known as antisense oligonucleotides (AONs) that hybridize to the 
pre-mRNA causing the skipping of the exon carrying the mutation. As result, the 
dystrophin reading frame is restored and a functional slightly shorter dystrophin 
protein is produced, similar to the truncated version found in patients with BMD 
(Helderman-van den Enden et al., 2010). Therefore the aim of exon-skipping 
therapy is to convert the severe DMD symptoms towards the much milder 
symptoms observed in BMD. The efficacy of this approach has been successfully 
demonstrated in preclinical in vivo studies, leading to different clinical trials for 
DMD patients (Kole and Krieg, 2015). Two drugs are currently being evaluated: 
PRO051 (Drisapersen) by Prosensa and GSK, and AVI-4658 (Eteplirsen) by 
Sarepta Therapeutics. Both of them target and induce skipping of exon 51 that is 
applicable to the largest group of all DMD patients (13%) (Helderman-van den 
Enden et al., 2010). However, they differ in their chemical composition. Initially, 
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the phase II clinical trial on Drisapersen gave encouraging results, indicating a 
slight increase in dystrophin production and a better performance of the treated 
DMD patients in the 6-Minute walk test (6MWT) (Voit et al., 2014). This test is 
widely used as an outcome measure in DMD, as it integrates the measurement 
of endurance, ambulation and muscle function (McDonald et al., 2010). 
Nevertheless, the phase III clinical trial has been prematurely interrupted since it 
failed to meet the primary endpoint of a statistically significant improvement on 
the 6MWT, possibly due to rapid clearance of the compounds from the 
circulation. Moreover, controversial interpretation of the results coming from 
these studies (i.e. the non-correlation of amount of dystrophin positive fibres via 
immunohistochemistry and the level of protein detected via Western blot 
analysis), revealed the need to refine those analytical approaches (Lu et al., 
2014). In a double-blind and open label treatment on Eteplirsen, the 
administration of the AONs led to dystrophin production in the muscles of DMD 
patients and a statistically significant advantage on 6MWT in comparison to 
historical controls, over 3 years of follow-up (Mendell et al., 2016). Moreover, a 
relative stability of respiratory muscle function and lack of toxicity were observed 
in this study, thus supporting further clinical investigations in larger cohorts of 
DMD patients.  
One of the limits of the exon skipping approach is that repeated administrations 
of the AONs are required since the effects are expected to be short-term. In 
order to provide sustained levels of dystrophin protein for a long-term therapeutic 
efficacy, modified small nuclear RNAs (U1 and U7snRNA) have been designed 
to shuttle AONs via recombinant adeno-associated virus (rAAV) vectors 
(Kawecka et al., 2015; Benchaouir and Goyenvalle, 2012). The potential of this 
approach has been shown in preclinical in vivo studies. In dystrophic mice a 
single treatment of rAAV-snRNA–mediated exon skipping systemically delivered 
was able to restore dystrophin levels and improved muscle function body-wide 
(Goyenvalle et al., 2012a; Denti et al., 2006; Goyenvalle et al., 2004). Recurrent 
treatments were required in dystrophic dogs to reach a therapeutic dose of rAAV 
vector (Le Guiner et al., 2014; Vulin et al., 2012). Although no adverse events 
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were apparent in the dog model, the vector doses used may potentially evoke 
AAV capsid-specific immune responses in human subjects, that could potentially 
undermine the safety and efficacy, as shown in other gene therapy trials based 
on AAV (Nathwani et al., 2014; Mingozzi et al., 2009). Another limit of the exon 
skipping approach is that it is restricted to specific mutations, warranting a 
personalized mutation-dependent treatment for different patients with different 
genotypes. Therefore, multiexon-skipping approaches to target exons 45-55 at 
the mutation hotspot of the DMD gene have been developed aiming to rescue up 
to 63% of DMD patients with a deletion (Goyenvalle et al., 2012b; Béroud et al., 
2007).  
Further improvements are needed to improve the overall efficiency of the exon-
skipping approach towards future clinical applications. 
 
1.2.3.2. Gene editing 
A recently developed and promising gene therapy strategy for the treatment of 
monogenic diseases, such as DMD, is based on the use of engineered 
endonucleases for site-specific correction of a mutated gene. Meganucleases 
(MGNs), zinc-finger nucleases (ZFNs), transcription activator-like effector 
nucleases (TALENs) and clustered regularly interspaced short palindromic 
repeats associated RNA-guided Cas9 (CRISPR/Cas9) nucleases are the classes 
of endonucleases that have been exploited for the editing of the dystrophin gene. 
The two different strategies validated for DMD are based on promoting the 
permanent removal of exon by non-homologous end joining (NHEJ) causing the 
disruption of the reading frame, thus leading to the production of a truncated 
dystrophin protein. Alternatively, full-length dystrophin expression could be 
restored by a homology-directed repair (HDR)-mediated insertion of correct gene 
sequence (Prakash et al., 2016). In primary myoblasts from DMD patients 
presenting the mutation in exon 51 locus (13% of patients), the dystrophin 
reading frame was restored by TALENs through the introduction of indels in the 
mutated exon (Ousterout et al., 2013) or by ZFNs that permanently excised exon 
51 (Ousterout et al., 2015a). With a similar approach, a multiplex CRISPR/Cas9-
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based system has been developed for the removal of exons 45-55 of DMD gene, 
a mutational hotspot which if targeted could be therapeutically applicable for 62% 
of patients (Ousterout et al., 2015b). These approaches resulted in a truncated 
but functional dystrophin protein. The mutational hotspot has also been targeted 
in immortalized myoblasts from DMD patients by MGN that mediated the 
homologous recombination knock-in of deleted exons 45-52 allowing the 
restoration of the full-length dystrophin (Popplewell et al., 2013). 
Interestingly, TALEN and CRISPR/Cas9 approaches have been used to 
successfully correct the dystrophin gene in iPSCs derived from a patient with a 
deletion in exon 44 (Li et al., 2015). Three different correction methods were 
applied: exon skipping, frameshifting and exon knock-in; with the latter approach 
able to restore the full-length dystrophin expression. 
Moreover, in vivo application of CRISPR/Cas9 has successfully shown the 
correction of the dystrophin gene in the germline of dystrophic mice. This led to 
dystrophin restoration and muscle phenotypic rescue in the progeny (Long et al., 
2014). In order to target post-mitotic adult tissues, the use of CRISPR/Cas9 
system was exploited in three different studies based on the delivery of gene 
editing components using AAV vectors in vivo in dystrophic mice 
(VandenDriessche and Chuah, 2016; Long et al., 2015; Nelson et al., 2015; 
Tabebordbar et al., 2015). These vectors could be delivered systemically and 
displayed high tropism for muscle. Results showed the expression of a truncated 
dystrophin upon excision of the mutated exon 23 and consequent rescue of the 
dystrophin reading frame. Although expression of dystrophin after gene 
correction was relatively low, a modest improvement in muscle function was 
reported which required high vector doses. In a recent study, CRISPR/Cas9 
nucleases alone or together with TALENs have been combined with adenoviral 
vectors (AdVs) to rescue the dystrophic phenotype in mdx mice (Xu et al., 2015) 
or genetically correct immortalized DMD myoblasts (Maggio et al., 2016). 
In contrast to transient methods based on AONs targeting the mRNA, 
endonucleases-based gene editing showed to permanently correct dystrophin 
mutations and therefore restore protein production, with the advantage of 
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obviating the need for continuous drug administration. However, optimization of 
these new gene-editing strategies to enhance safety (i.e. to minimize the risk of 
off-target sites) and protein expression levels is needed for potential clinical 
translation. 
 
1.2.3.3. Gene addition 
Gene addition strategies have successfully shown the possibility to provide an 
additional functional copy of the dystrophin gene that overcomes the genetic 
defect caused by a mutation in dystrophin. In this way, the expression of the 
missing protein is restored and the muscle function recovered, regardless of the 
type of mutation.  Consequently, gene addition is potentially suitable for all the 
DMD patients. Nevertheless, achieving safety and demonstrating long-term 
efficiency by gene addition remains challenging. This is compounded by potential 
immune responses against the vector or the new protein expressed by the 
therapeutic gene. Another challenge relates to the abundance of the muscle 
tissues that need to be targeted in muscular dystrophies. Since the fibers are 
surrounded by connective and sometimes fibrotic tissue this may also affect the 
efficiency of delivering the therapeutic gene. The types of vectors currently in use 
for the treatment of muscular dystrophies can be divided in viral and non-viral 
vectors. 
Viral vectors have the ability to relatively efficiently transduce different cell types 
and have been exploited as gene transfer vehicle for in vivo and ex vivo gene 
therapy approaches for DMD. Helper-dependent adenoviral (HDAd) vectors have 
a cargo up to 36 Kb and can easily accommodate the full-length dystrophin 
cDNA  (14 Kb), resulting in its efficient expression (Guse et al., 2012; Kawano et 
al., 2008). Nevertheless, the applicability of this approach in vivo is limited by the 
need of multiple intramuscular administrations of HDAd vectors and the high risk 
of immune response, as previously showed in non-human primates (Brunetti-
Pierri et al., 2004; Zoltick et al., 2001). Moreover, systemic administration of 
adenoviral vectors has been shown to result in acute inflammation and significant 
morbidity and mortality in clinical trials (Wilson, 2009). 
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Recombinant adeno-associated virus (rAAV) vectors overcome some of these 
hurdles, since they can be systemically delivered to efficiently target skeletal and 
cardiac muscles in vivo (Wang et al., 2005; Gregorevic et al., 2004) and exhibit 
low immunogenicity compared to HDAd vectors (Zaiss et al., 2002). However, 
the relatively limited packaging capacity of rAAV vectors (~4.5 Kb) precludes the 
incorporation of large transgenes such as the full-length dystrophin cDNA (14 
Kb). Therefore, truncated but functional versions of the dystrophin cDNA have 
been generated that mimick the truncated, partially functional dystrophins 
characteristic in BMD patients (minidystrophins).  Alternatively, only regions 
necessary for recruiting important dystrophin binding partners can be retained  
(microdystrophin) (Figure 4). Preclinical in vivo studies have shown that a single 
systemic administration of rAAV vectors coding for microdystrophin improves 
muscle function and rescues the dystrophic phenotype in mice (Koppanati et al., 
2010; Wang et al., 2009; Gregorevic et al., 2006). Nevertheless, the translation to 
large size animal models for DMD and to patients is challenging, due to an 
immune response against the rAAV vectors and the transgene product itself 
(Bowles et al., 2012; Shin et al., 2012; Kornegay et al., 2010; Ohshima et al., 
2009; Wang et al., 2007a, 2007b; Yuasa et al., 2007). These adverse events 
were responsible for the lack of long-term microdystrophin expression. Therefore, 
in order to increase the specificity towards the target cells and elicit an immune 
response to sustain high levels of expression of the protein, improvements on the 
design of gene delivery vectors have been reported. These consisted in the 
optimization of the transgene sequence (Athanasopoulos et al., 2011; Foster et 
al., 2008), the use of muscle-restricted promoters and enhancer transcriptional 
elements (Koo et al., 2011a, 2011b; Salva et al., 2007), the development of viral 
capsids with reduced immunogenic profile (Yue et al., 2015; Shin et al., 2013; 
Rodino-Klapac et al., 2010). The combination of these features, together with 
long-term studies on immunity in large animal models for DMD, would be 
required for ultimate clinical translation.  
In contrast to rAAV, lentiviral vectors show a larger size capability (~ 9-10 Kb) 
and have been exploited to develop ex vivo gene therapy approaches for DMD. 
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However, vector titers dropped significantly with increased vector size.  Muscle 
progenitors isolated from dystrophic animals and genetically corrected using 
lentiviral vectors coding for truncated forms of the dystrophin cDNA have been 
transplanted in dystrophic recipients. The dystrophin expression was successfully 
restored in the fibers of the treated muscles (Meng et al., 2016; Sampaolesi et 
al., 2006; Li et al., 2005a; Bachrach et al., 2004). Although this approach might 
represent a valid platform for the development of an autologous stem cell-based 
gene therapy, preclinical in vivo studies in dystrophic dogs have shown that 
microdystrophin does not replicate all of the essential functions of the full-length 
dystrophin (Sampaolesi et al., 2006). This strategy was effective to treat other 
muscular dystrophies where the smaller size of the therapeutic transgene 
facilitated gene delivery by lentiviral vectors (Meregalli et al., 2013; Tedesco et 
al., 2012; Sampaolesi et al., 2003). Although lentiviral vectors are efficient and 
relatively safe, as demonstrated by the successful on-going clinical trials for 
inherited diseases (Aiuti et al., 2013; Biffi et al., 2013), their use is hampered by 
the risk of insertional mutagenesis. To circumvent this problem, non-integrating 
integrase-defective lentiviral (IDLV) vectors have been recently generated 
(Vargas et al., 2004). Though IDLVs may enable gene transfer in post-mitotic 
tissues such as muscles (Kymäläinen et al., 2014), the levels of expression and 
the transduction efficiency are generally low. In this context, the use of non-viral 
vectors can be considered as a valid alternative for gene transfer-based 
therapies for muscular dystrophies. 
 
Non-viral vectors evoke only limited or no adaptive immune responses and can 
transfer genetic material of various sizes. These features make them particularly 
attractive to treat diseases caused by mutations in large genes, such as DMD.  
Naked plasmids coding for the full-length dystrophin have been employed for 
direct intramuscular injection in DMD patients (Romero et al., 2004). Although no 
adverse effects have been observed, this approach was limited to a defined area 
of the treated muscle and the expression of the protein was not sustained. 
Therefore new methods were considered to deliver the therapeutic gene 
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systemically, such as the hydrodynamic limb vein (HLV) injection (Herweijer and 
Wolff, 2007). Preclinical studies in dystrophic mice showed that the application of 
this method led to the restoration of the full-length dystrophin expression into the 
lower limbs and long-term protection of skeletal muscles (Zhang et al., 2010). 
Interestingly, studies on dose-response in rodents and nonhuman primates 
supported the use of HLV injection for possible therapeutic treatments of patients 
affected by DMD and other muscular dystrophies (Wooddell et al., 2011; Hegge 
et al., 2010). Alternatively, naked plasmids have been used in combination with a 
site-specific recombinase called phiC31 integrase to deliver the full-length murine 
dystrophin cDNA in mdx iPSCs (Zhao et al., 2014). The genetically corrected 
iPSCs were enriched for a common marker of murine muscle precursor cells 
(SM/C 2.6) and differentiated in myogenic precursors able to express the 
dystrophin in vitro and in vivo. However myogenic induction was relatively 
inefficient and further studies are necessary to make this approach applicable to 
human iPSCs. 
 
The human artificial chromosome (HAC) is a non-integrating non-viral vector that 
can be stable maintained as an endogenous chromosome throughout 
subsequent cell divisions (Kouprina et al., 2014; Kazuki and Oshimura, 2011). 
DYS-HAC has been generated that contained the entire human dystrophin gene 
(2.4 Mb), including the regulatory elements (Hoshiya et al., 2009). Notably, in 
2011, Cossu’s group demonstrated the possibility of exploiting MABs for a cell-
mediated non-viral gene replacement approach for DMD (Tedesco et al., 2011) 
based on DYS-HAC. Dystrophic murine MABs genetically corrected with DYS-
HAC were transplanted in immunodeficient dystrophic (scid/mdx) mice.  This 
resulted in human dystrophin expression in the muscle fibers of the recipient 
animals consistent with long-term functional amelioration of the dystrophic 
phenotype. In the next study from the same team, mesoangioblasts have been 
derived from iPSCs of a DMD patient genetically corrected with DYS-HAC, 
paving the way to future studies for autologous gene therapy approaches 
(Tedesco, 2015; Tedesco et al., 2012). However, the transfer of such a large size 
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vector into the target cells results quite challenging and efficiency is affected 
(approximately 1.2 x 10-5). Moreover the production of such a complex vector 
makes it costly and time consuming. Therefore, further studies are needed in 
order to improve this technology and move towards a clinical application. 
 
Figure 4. Schematic representation of the truncated mini- and microdystrophin 
versions. Examples of mini- and micro- dystrophin genes that have been developed by 
different groups for vector-mediated gene addition strategies for DMD. The full-length 
dystrophin structure is shown uppermost, and features the same terminology as that 
used in Figure 1. The two actin-binding domains of the dystrophin are indicated as AB1 
and AB2. The name of the mini-dystrophin version from Davie’s lab indicates the 
deletion of exons corresponding to the sequence represented, at variance with the other 
mini- and microdystrophin versions where the name of the missing protein domains are 
indicated. In the microdystrophin mutants, ΔC indicates the deletion of the CT domain. 
Adapted from (McGreevy et al., 2015). 
 
1.3. Transposons 
Transposons represent a valid non-viral vector system alternative to the several 
methods currently under investigation, aimed at developing safe and efficient 
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gene therapy approaches for monogenic disorders. Transposons are plasmid-
based non-viral vectors able to transfer the gene of interest into the genome of 
the target cells. The advantage of this gene delivery system is that it can stably 
integrate into the genome and achieve a prolonged expression of the transgene, 
while retaining the features of a non-viral vector system: low immunogenic 
profile, reduced risk of insertional mutagenesis, large cargo capability, easy 
manufacturing (Koonin and Krupovic, 2015; Loperfido et al., 2015a; Di Matteo et 
al., 2014a; Mátés et al., 2009; VandenDriessche et al., 2009).  
In nature, DNA transposons are primitive genetic elements that have the ability to 
move within, and shape, the host genome (McClintock, 1950). On the other 
hand, transposons are regulated by host defensive mechanisms and self-
inhibitory systems to reduce harm to the host genome (Biémont, 2009). 
Transposable elements present in the eukaryotic chromosomes are designated 
as class I (RNA-based) transposons when they encode for an intermediate 
mRNA transcript, followed by a “copy and paste” mechanism to move around. 
Whilst they are defined as class II (DNA-based) transposons when they jump 
from one site to another one by a “cut and paste” mechanism that is catalyzed by 
a transposase protein. This enzyme is encoded by the element itself. Indeed, 
class II transposons consist of a single gene coding for the transposase, flanked 
by terminal inverted repeats (IRs) that contain specific binding sites for the 
protein. When the transposase recognizes and binds the IRs, DNA mobilization 
occurs by recombinase activity.  These features made transposable elements 
attractive as gene delivery tools: the transposase gene can be separated from 
the IRs and replaced by any other DNA sequence of interest. For mobilization, 
the new gene has to be supplied together with the transposase that is provided 
either as a plasmid or mRNA (Yant et al., 2000). To be effective and safe as 
gene delivery tools, transposon systems should show high transposition activity 
in the host cells and should be phylogenetically distant from the targeted host 
genome (Skipper et al., 2013). Indeed, endogenous copies of transposon should 
be absent in the target genome, in order to avoid remobilization of resident 
copies (Mátés et al., 2007).  
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1.3.1. Transposons as gene therapy tools 
Numerous studies have enhanced the capacity of the transposons to efficiently 
transfer and stably express the gene of interest in mammalian cells, in order to 
obtain promising tools for human gene therapy (Meir and Wu, 2011). The most 
effective systems in mammalian cells to date are the salmonid transposon 
Sleeping Beauty (SB) and the insect-derived natural element piggyBac (PB), thus 
representing the most promising transposons for gene therapy. 
 
1.3.1.1. Sleeping Beauty 
The salmonid transposon Sleeping Beauty is a member of the ancient 
Tc1/mariner-like elements that are prevalent in many fish genomes but not 
functional, due to accumulation of inactivating mutations (Plasterk et al., 1999). 
Based on phylogenetic studies, the salmonid transposase was “re-awakened” 
from its evolutionary dormancy through a series of mutagenesis steps, from 
which the name Sleeping Beauty (SB) (Ivics et al., 1997). In its natural 
configuration, the SB transposon is 1.6 Kb long and consists of a single gene 
coding for a transposase protein, flanked by two 230 bp terminal IRs. Each IR 
contains two 32 bp not identical direct repeats (DRs) that are the binding sites for 
the SB transposase (Cui et al., 2002). This protein is 360 amino acid-long and is 
composed of a N-terminal DNA-binding domain, a nuclear localization signal 
(NLS) and a C-terminal catalytic domain (Ivics et al., 1996). The NLS is located 
between the two domains and is important for nuclear import of the protein. 
Binding of a single transposase through the DNA-binding domain to each DRs 
into the terminal IRs results in the generation of a synaptic complex, in which the 
two ends of the transposon are held together by a tetramer of transposases 
(Izsvák et al., 2002). The transposon is excised from the donor locus by the 
catalytic domain and re-inserted into the TA-dinucleotide of the target sequences 
(Ivics et al., 1997). The aspartate-aspartate-glutamate (DDE) motif is an 
important conserved amino acid triad in the catalytic domain of the SB 
transposase, as well as in other recombinases (Plasterk et al., 1999). Deletions 
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in the DDE motif abrogate the catalytic activity. Upon transposition, the DNA 
repair machine by host enzymes creates a characteristic footprint at the excision 
site and a duplication of TA-dinucleotide at the integration site (Yant et al., 2005; 
Vigdal et al., 2002). Interestingly, SB transposons exhibit a nearly random 
integration profile with no preferential integration into active genes (~35% into 
RefSeqGenes; (Mátés et al., 2009; Yant et al., 2005; Huang et al., 2010)), thus 
representing a safer system for possible gene therapy applications compared to 
when integrating viral vectors are employed (Moldt et al., 2011; Hackett et al., 
2007; Berry et al., 2006). 
Transposition of SB is inhibited by elevated levels of transposase, a 
phenomenon called overproduction inhibition and indicating self-regulatory 
mechanisms developed during the evolution (Lohe and Hartl, 1996). Therefore in 
the engineered systems for gene delivery, the ratio of transposase DNA: 
transposon DNA would require optimization (Geurts et al., 2003). Moreover, SB 
transposase interacts with cellular cofactors such as HMGB1 and Miz-1, which 
might influence the overall transposition efficiency supporting the possible effect 
of a cell type on the SB transposition (Walisko et al., 2006; Zayed et al., 2003),   
The high activity of SB transposon system in mammalian cells has been 
exploited for non-viral vector gene therapy studies (Hackett et al., 2010; Izsvák et 
al., 2010; Ivics and Izsvák, 2006; Yant et al., 2004). The SB transposase and the 
SB transposon encoding the gene of interest have been used as gene delivery 
tools both in vivo in preclinical animal models (Hackett et al., 2011), as well as ex 
vivo in clinically relevant cells (Swierczek et al., 2012; Ivics and Izsvák, 2011). 
Initial studies showed a low efficiency in stable gene transposition, therefore the 
SB transposase has been engineered to produce hyperactive versions (Mátés et 
al., 2009; Baus et al., 2005; Yant et al., 2004). To date, the most hyperactive 
engineered SB transposase, called SB100X, has been first characterized by our 
team in collaboration with Izsvák’s group (Mátés et al., 2009). SB100X 
transposase showed a robust 100-fold increase in transposition in human cell 
lines when compared to the first generation transposase SB. The superior gene 
transfer efficiency of SB100X transposase has been demonstrated in human 
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hematopoietic stem cells (Mátés et al., 2009; Xue et al., 2009), mesenchymal 
stem cells and muscle stem/progenitor cells (Filareto et al., 2015; Marg et al., 
2014; Belay et al., 2010), T cells (Jin et al., 2011) and for reprogramming and 
targeted gene insertion in iPSCs (Filareto et al., 2013; Grabundzija et al., 2013; 
Belay et al., 2010). Moreover, the hyperactive SB100X transposase was 
exploited to obtain highly efficient germline transgenesis (Ivics et al., 2014a, 
2014b, 2014c) and for in vivo transposition of therapeutically relevant genes 
(Hausl et al., 2010; Mátés et al., 2009). However, one of the limits of SB 
transposon system is the loss of transposition efficiency with large size inserts (> 
5.6 Kb, (Karsi et al., 2001)). Therefore a "sandwich" SB transposon was 
generated, in which the DNA to be mobilized is flanked by two complete terminal 
IRs arranged in an inverted orientation. The sandwich SB transposon has 
superior ability to transfer >10 Kb transgenes, thereby extending the cloning 
capacity of the system (Turchiano et al., 2014; Zayed et al., 2004). 
Remarkably, a first-in-human clinical trial has been recently approved utilizing the 
SB transposon system to treat patients with CD19+ B-lymphoid malignancies 
(Trial ID: US-0922; (Kebriaei et al., 2012; Williams, 2008)). Autologous T cells 
have been modified with SB vectors carrying chimeric antigen receptor (CAR) to 
make the T cells cytotoxic specifically toward CD19+ malignant cells and induce 
cancer regression. Although SB transposon system exhibits a nearly random 
integration pattern not associated with genotoxicity in T cells (Huang et al., 
2010), however further studies to improve the transposition efficiency with 
minimal side effects need to be performed (Hackett et al., 2013; Meir and Wu, 
2011). 
 
1.3.1.2. piggyBac 
PiggyBac (PB) transposon system is another efficient transposable element for 
gene transfer in mammalian cells. It was first discovered by mutational insertions 
within the Baculovirus genome present in the insect cell line TN-368, from the 
cabbage looper moth Trichoplusia ni of the order Lepidoptera (Fraser et al., 
1985, 1983). In its natural configuration, the PB element is 2.4 Kb long and 
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consists of a single gene coding for a transposase protein flanked by two 13-bp 
terminal IRs and additional asymmetric 19-bp internal IRs (Fraser et al., 1995; 
Cary et al., 1989). The PB transposase enzyme is a 594 amino acid-long DNA-
binding protein with a nuclear localization signal in the C-terminal region, 
necessary for its efficient translocation to the nucleus. The N-terminal sequence 
contains a highly conserved DDE/DDD catalytic domain with recombinase 
properties and necessary for DNA editing (Keith et al., 2008; Mitra et al., 2008). 
Catalytically inactive mutant transposases have been recently generated by 
introducing mutations in the DDD sequence (Burnight et al., 2012).  
The PB transposase catalyzes transposition through a cut and paste mechanism. 
Differently from SB transposition, PB insertions into the target genome occur 
preferentially at TTAA nucleotide sequences without any deletion or duplication, 
thus bypassing DNA synthesis (Figure 5; (Mitra et al., 2008; Fraser et al., 1996, 
1995; Cary et al., 1989)). Moreover, the genomic integration profile exhibits a 
slight tendency of PB to integrate in genes and their regulatory regions (~50% 
into RefSeqGenes) (Burnight et al., 2012; Doherty et al., 2012; Meir et al., 2011; 
Grabundzija et al., 2010; Huang et al., 2010; Galvan et al., 2009; Wilson et al., 
2007). Nevertheless, most of the intergenic insertions (~90%) take place in 
intronic regions, followed by 3’UTRs, 5’UTRs and a minimal percentage in exonic 
regions (3%) (Meir et al., 2013; Ding et al., 2005). Interestingly, the nonrandom 
integration profile of PB in clinically relevant cells such as primary human T cells 
is not associated with genotoxicity and results to be safer compared to γ-
retroviral and lentiviral vectors (Galvan et al., 2009). On the contrary, a recent 
study has shown a random integration pattern of PB in the genome of 
mesoangioblasts, another clinical relevant cell type (Ley et al., 2014). In order to 
direct the integration into specific “safe harbor” loci that virtually carry no risk of 
insertional mutagenesis (i.e. chemokine C-C motif receptor 5, CCR5), a 
heterologous DNA sequence-specific DNA-binding domain (DBD) was fused with 
the transposase enzyme (Voigt et al., 2008). In contrast to the SB transposase 
whose activity was compromised upon N-terminal or C-terminal fusions, PB 
transposase function was minimally perturbed when fused with different protein 
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domains. This enabled site-specific integration into the genome of human cells 
(Meir et al., 2013; Owens et al., 2013; Doherty et al., 2012; Owens et al., 2012; 
Kettlun et al., 2011; Wilson and George, 2010; Cadiñanos and Bradley, 2007). 
However, further studies are needed to improve the efficiency and specificity of 
this approach, as well as the exclusion of possible off-target effects. 
The PB transposon system has been shown to enable efficient transposition in 
mice and in human cells (Wilson et al., 2007; Ding et al., 2005), thus emerging as 
an attractive vehicle for non-viral gene therapy studies. In contrast to the SB 
transposon system, PB transposition is not dependent on interaction with cellular 
co-factors and is not limited by overproduction inhibition (Wilson et al., 2007). In 
order to increase expression levels and enhance transposition activity, a new 
transposase designed as mPB has been generated for mammalian expression 
by a codon usage optimization of the original insect PB (iPB) transposase gene 
(Cadiñanos and Bradley, 2007). In addition, a hyperactive PB transposase 
named hyPB has been recently developed by introducing seven individual amino 
acid substitutions in the sequence of the mPB transposase (Yusa et al., 2011). 
The hyPB transposase has shown a protein level three times higher than mPB 
transposase, 17-fold increase in excision activity and 9-fold enhanced integration 
activity in mouse ESCs without significantly affecting the genomic integrity. The 
superior transposition activity of hyPB has been demonstrated also in human 
cells and in vivo in mice, in a head-to-head comparison with SB100X 
transposase (Doherty et al., 2012). Another strategy used to improve 
transposition consisted of modifying the PB transposon terminal IRs (Li et al., 
2005b, 2001). PB transposons carrying mutant terminal IRs named enhanced 
piggyBac (ePB) led to a 90% increase in transposition efficiency in human ESCs 
compared to when the original IRs sequences were deployed (Lacoste et al., 
2009).  In addition, the ePB transposon system was able to boost the original PB 
cargo capacity of maximum 14.3 Kb insert size, allowing the delivery of inserts up 
to 18 Kb in size. However, transposition efficiency decreased significantly for 
inserts larger than 12 Kb. Alternatively, PB transposons lacking all the non-
essential sequences in the terminal IRs, and therefore reduced in size, have 
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been shown to result in a a 1.5-fold increase in transposition activity when 
compared to the original version (Meir et al., 2011). Interestingly, when the 
terminal IRs sequences of the PB transposon were cloned into the bacterial 
artificial chromosome (BAC), the mobilization of a 100 Kb fragment was achieved 
in mouse ESCs (Li et al., 2011). This accomplishment made PB transposon 
system particularly attractive for the delivery of large therapeutic genes or 
multiple genes together, thus circumventing the size restrictions of viral vectors 
and other transposons.  
The potential of PB transposon system as a gene therapy tool has been 
exploited in studies with preclinical animal models (Di Matteo et al., 2014a; 
Matsui et al., 2014) and clinically relevant cell types such as mesoangioblasts 
(Ley et al., 2014), mesenchymal stem cells (Wen et al., 2014), human 
hematopoietic stem cells (Grabundzija et al., 2010) and human primary T cells 
(Galvan et al., 2009; Nakazawa et al., 2009). The iPB transposon system has 
been used as an efficient alternative to SB to modify primary T cells for different 
purposes: to generate CD19-specific CAR T cells for the treatment of B-lineage 
malignancies (Saito et al., 2014; Manuri et al., 2010), to modify Epstein Barr 
virus-specific cytotoxic T lymphocytes (EBV-CTLs) and target HER2-positive 
cancer cells (Nakazawa et al., 2011), to render T cells resistant to rapamycin and 
direct them against B lymphomas (Huye et al., 2011). For future applications in 
cancer immunotherapy, the hyPB transposon system is a promising candidate.  
Although iPB has shown a similar efficiency in transposition when compared to 
SB100X (Huang et al., 2010), the latest hyPB is  2 to 3-fold more efficient than 
either the iPB or SB100X as a gene delivery system in primary T cells (Doherty 
et al., 2012).  
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Figure 5. Mechanism of PB transposition. Once transposase is expressed (red 
circles), it binds to the piggyBac IRs and induces a hairpin formation. Transposon is 
excised and joined into the target genome at a TTAA nucleotide sequence, resulting in 
TTAA target site duplication at the genomic locus. If precise excision is desired, 
transposase can be re-expressed and the transposon can be excised, thereby recreating 
the original TTAA target site at the original locus. Adapted from (Woodard and Wilson, 
2015). 
 
1.3.1.3. Transposon delivery into target cells 
Unlike viral vectors that have developed efficient mechanisms to transfer their 
genetic material directly into the nucleus of the target cells, the transposon 
system requires efficient methods to permeate the cellular membranes. 
Consequently, gene delivery methods commonly used for non-viral vectors or 
alternatively viral/non-viral hybrid technologies have been exploited for the 
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transposon-based gene delivery. Hybrid technologies take advantage of the 
ability of the viral vector to transduce cells. In particular, IDLV (Cai et al., 2014; 
Moldt et al., 2011; Staunstrup et al., 2009; Vink et al., 2009), retroviral (Galla et 
al., 2011), herpes simplex (de Silva et al., 2010; Bowers et al., 2006) and 
adenoviral vectors (Hausl et al., 2010; Yant et al., 2002) have been used to 
transfer the transposon system into the target cells either in vitro or in vivo. 
Nevertheless, these hybrid technologies are characterized by some of the 
intrinsic disadvantages of viral vectors, outlined above, such as manufacturing 
hurdles and possible immune reactions. 
Non-viral vector delivery methods are simpler and potentially safer than viral 
vectors, although achieving high transfection efficiencies, prolonged gene 
expression and low toxicity is challenging. Transposase and transposon plasmids 
can be delivered through physical methods such as electroporation (Hollis et al., 
2006), hydrodynamic injection (Yant et al., 2000), sonoporation (Chen et al., 
2012) or chemical carriers such as nanoparticles (Kren et al., 2009) and 
polycation-based DNA complexes (i.e. lipofectamine and polyethyleneamine, (Li 
et al., 2011; Podetz-Pedersen et al., 2010)).  
Electroporation is a delivery technology that consists in exposing cells to high-
voltage pulses of electricity that creates transient pores in the cell membrane, 
promoting DNA transfer. Although some cells die in the process, this approach is 
applicable to almost all types of cells. Nucleofection technology is an 
electroporation-based method effective even in “hard-to-transfect” primary and 
pluripotent stem cells. It combines electrical parameters and cell type-specific 
buffer solutions to directly deliver the DNA into the cell nucleus. In contrast to 
other non-viral vector delivery methods that rely on cell division for the DNA 
transfer into the nucleus, the transfection of the target cells by nucleofection 
occurs independent from the cell cycle status. Nevertheless, nucleofection 
technology also adversely affects cell viability. Therefore optimization of the 
transfection reactions is necessary for each cell type and is generally achieved 
by varying the ratio of the two plasmids transposase DNA: transposon DNA 
(Izsvák et al., 2009). 
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The host lab and other groups established proof-of-concept that nucleofection of 
transposons is effective in hard-to-transfect primary cells. In particular, delivery of 
the transposon system by nucleofection in clinically relevant cells yielded a stable 
expression of the genes of interest corresponding to 35-50% in human 
hematopoietic stem/progenitor cells (Mátés et al., 2009), 40-50% in T cells 
(Manuri et al., 2010; Nakazawa et al., 2009), 30-40% in mesenchymal 
stem/progenitor  cells and muscle stem/progenitor cells (Belay et al., 2010) and 
25% in pluripotent stem cells (Belay et al., 2010). Therefore, nucleofection 
represents a promising technology for transposon-mediated delivery of large 
therapeutic genes.  
 
1.3.2. Transposons for muscle disorders  
Recent studies have explored the use of SB and PB transposon systems to 
develop therapeutic strategies for muscular dystrophies. Muscle stem/progenitor 
cells (satellite cells/myoblasts) are relevant targets for muscle regeneration and 
for gene therapy in muscle disorders. The host lab was the first to demonstrate 
that primary human myoblasts can be manipulated in vitro with the SB 
transposon system without affecting their myogenic potential (Belay et al., 2010). 
In order to overcome the limited proliferation capacity of these primary cells, 
conditionally immortal myoblast cell lines were generated (Escobar et al., 2016; 
Muses et al., 2011a). SB transposons have been shown to efficiently integrate 
into immortalized myoblasts and stably express the green fluorescent protein 
(GFP) reporter transgene (Muses et al., 2011a) as well as therapeutic genes 
such as microdystrophin (size: 3.6 Kb; (Muses et al., 2011b)) and full-length 
dysferlin (DYSF; size: 6.2 Kb; (Escobar et al., 2016)). Genetically corrected 
immortal myoblast cell lines retained their myogenic potential in vitro and in vivo. 
Although these immortalized myoblasts represent a reliable model to investigate 
stem cell based therapies for muscle disease, they cannot be deployed clinically. 
Consequently, different studies have focused on the development of tools for the 
enrichment and the expansion of satellite cells in culture, while maintaining their 
stem cell regenerative properties (Filareto et al., 2015; Marg et al., 2014). In 
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these studies, SB-mediated gene transfer was applied successfully to cultured 
satellite cells allowing a stable expression of the GFP reporter or the 
microdystrophin transgene (size: 3.6 Kb) upon cell transplantation, and 
contribution to muscle regeneration in vivo. As an alternative, other cell types 
with myogenic potential and clinically relevant for the treatment of muscle 
disorders such as mesoangioblasts (Cossu et al., 2015) have been investigated 
for a possible application of PB transposon vectors (Ley et al., 2014). In this 
study, it has been shown that the PB enables sustained expression of the GFP 
reporter gene in cultured mesoangioblasts and upon their differentiation into 
muscle fibers following transplantation. Moreover, the PB integration profile 
resulted to be nearly random (73 % of the recovered integration events were 
found in intergenic regions) and therefore relatively safe, supporting the use of 
PB transposon system in stem cell-based gene therapy studies for muscle 
disorders.  
However, the regenerative potential of these genetically modified adult 
stem/progenitor cells is not unlimited and exhaustion/dysfunction of muscle 
stem/progenitor cells has been reported in several muscular dystrophies and/or 
after expansion in vitro. Different protocols have been developed to obtain an 
efficient directed differentiation of the pluripotent stem cells into myogenic cells 
(see above, Table 2 and Table 3; reviewed in (Loperfido et al., 2015a)). 
Transposon technology has been used to genetically modify ESCs and iPSCs.  
In the work of (Belay et al., 2010), the host lab has showed that SB-mediated 
Pax3 gene transfer in murine iPSCs coaxed their differentiation into 
multinucleated MyoD+MyHC+ myotubes. Alternatively, a PB-mediated MyoD 
inducible system was used for myogenic differentiation of human iPSC from 
patients with Miyoshi myopathy (MM), an inherited muscular dystrophy caused 
by DYSF mutations, and for carnitine palmitoyltransferase II deficiency, an 
inherited myopathy caused by mutations in CPT2 (Yasuno et al., 2014; Tanaka 
et al., 2013). The resulting human MyoD-iPSCs were able to undergo direct 
myogenic differentiation without a mesodermal transition step (10 days). 
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Nevertheless, the in vivo regenerative potential of the myogenic cells derived 
using this method remains to be determined. 
In the work of Filareto et al. the dystrophic phenotype of dystrophin/utrophin null 
mouse iPSCs was corrected by expressing micro-utrophin (μUTRN; size: 3.5 
Kb) with the SB transposon system (Filareto et al., 2013). Upon myogenic 
differentiation, the genetically corrected cells were transplanted in 
dystrophin/utrophin null mice and contributed to muscle regeneration and 
improvement in contractility. This study does not represent dystrophin/DMD gene 
correction sensu stricto, as the defective dystrophin is replaced by utrophin, 
which may not replicate all of the essential functions of dystrophin. Importantly, 
this strategy is so far limited to mouse iPSCs and data supporting its validity 
using DMD iPSCs will be necessary in order to consider potential clinical 
translation (Loperfido et al., 2015a). Using the PB transposon system expressing 
the full-length DYSF transgene, correction of human iPSCs derived from patients 
affected by MM was achieved (Tanaka et al., 2013). In particular, restoration of 
expression of the missing protein has been detected in vitro on the membrane of 
genetically corrected MM human iPSC-derived myotubes. Moreover the 
expression of full-length DYSF by the therapeutic transgene rescued the MM 
phenotype, as demonstrated by an improvement in the defective membrane 
repair phenotype of MM myotubes during in vitro functional tests such as two-
photon laser-induced injury of the sarcolemma. Transplantation in MM animal 
models is expected to move this strategy forward. Though these previously 
mentioned studies demonstrated the validity of using transposons as a tool to 
genetically correct iPSCs derived from patients with muscular dystrophies, it has 
not yet been shown that they can be used for the delivery of the full-length 
dystrophin transgene into patient iPSCs or their myogenic progeny or into 
mesoangioblasts sensu stricto. 
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Chapter 2 
 
2. Objectives of the Research 
2.1. General objective 
Gene therapy for DMD is particularly challenging given the large size of the 
dystrophin gene (2.4 Mb) and its corresponding coding DNA sequence (CDS, 
11.1 Kb). Consequently, the dystrophin CDS cannot readily be accommodated 
into most of the commonly used viral vectors. This is compounded by the 
immune challenges associated with the use of viral vectors as opposed to when 
non-viral gene delivery systems are used. To overcome these limitations, a non-
viral vector based ex vivo gene therapy strategy will be developed based on the 
stable genetic modification of dystrophic myogenic stem/progenitor cells with 
transposons encoding the full-length dystrophin CDS.  
 
The main objective of my PhD thesis was to address this unmet need and to 
develop and validate a novel stem cell-based non-viral vector gene therapy 
approach for DMD using the latest-generation piggyBac (PB) transposons 
encoding the full-length human dystrophin CDS. The main advantage of using 
PB transposons as gene delivery tools over the commonly used vector systems 
is to attributed to their large cargo capability, a low immunogenic profile, easy 
manufacturing and the ability to achieve long-term transgene expression upon 
their stable integration in the target genome. In order to accomplish this, we 
genetically modified distinct myogenic stem/progenitor cells including vessel-
associated pericyte-like mesoangioblasts (MABs) and human iPSC-derived 
mesoangioblasts (HIDEMs). The peculiarity of these types of cells is based on 
their ability to extravasate from the circulation and differentiate into functional 
differentiated muscle fibers. We therefore wish to address the following specific 
hypotheses. 
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2.2. Specific aims 
1) Does the latest-generation hyperactive PB platform result in stable 
reporter gene expression in normal murine myoblast cells (i.e. C2C12), 
dystrophic MABs isolated from the skeletal muscle of a large animal model 
of DMD (i.e. Golden Retriever muscular dystrophy dog, GRMD) and DMD 
patient-specific HIDEMs? 
 
2) Can sustained expression of truncated or full-length human dystrophin be 
achieved in vitro after stable transposition in dystrophic GRMD MABs or 
DMD patient-specific HIDEMs after induction of myogenic differentiation?  
 
3) Can we detect dystrophin expression in vivo after transplantation of DMD 
patient-specific HIDEMs engineered with the PB transposon encoding the 
full-length human dystrophin in dystrophic immunodeficient scid/mdx 
mice? 
 
If successful, this would establish the first proof of concept study of a gene 
therapy approach for DMD based on PB transposon-mediated expression of a 
functional full-length dystrophin, paving the way towards the development of new 
protocols for autologous cell therapy. 
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Chapter 3 
 
3. Methodology and Materials 
3.1.  Cells and culture conditions 
Biopsies from Golden Retriever muscular dystrophy (GRMD) dogs were kindly 
provided by Dr. Richard and Dr. Hubert-Martrou from Le Centre de Boisbonne-
ONIRIS (Nantes-Atlantique, France). This colony of GRMD dogs presents a A-
>G mutation in the acceptor splice site of intron 6 of the dystrophin gene that 
causes the skipping of exon 7 and a premature termination of translation. 
Canine mesoangioblasts (MABs) were isolated from the limb muscles of the 
GRMD dogs and maintained in culture, as described previously (Sampaolesi et 
al., 2006; Tonlorenzi et al., 2007). Briefly, a biopsy from the Vastus lateralis 
muscle of a 10-month-old male dog was minced in 1mm2 pieces. These 
fragments were transferred onto collagen type I-coated dishes (C8919, Sigma-
Aldrich) and incubated in growth medium composed of MegaCell DMEM 
(Dulbecco’s modified Eagle’s medium, M3942, Sigma-Aldrich) containing 5% 
fetal bovine serum (FBS, 10270-106, Gibco), 0.1 mM β -mercaptoethanol 
(31350-010, Gibco), 1% MEM non-essential amino acids (Gibco), 1% penicillin/ 
streptomycin (P/S, 15140122, Gibco), 1% L-glutamine (25030024, Gibco), 5 
ng/ml recombinant human fibroblast growth factor-basic (FGF-b, PHG0261, 
Gibco) at 37 °C in a 5% CO2, 3% O2 cell culture incubator. After 5 to 7 days, 
small, round, refractile cells that adhered weakly to the initial cell outgrowth were 
identified. This cell population was collected and maintained in growth medium 
on collagen-coated flasks. In order to confirm that the identified population was 
composed of bona fide MABs, cells were characterized for the typical markers of 
adult dog MABs, after five and ten passages. The alkaline phosphatase (AP) 
expression was detected by enzymatic activity using the NBT/BCIP kit 
(11697471001, Roche). The staining was performed on fixed cells in order to 
allow the formation of a black/purple precipitate in the cells expressing the 
enzyme. Moreover, their capacity to differentiate into mesodermal lineages was 
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analyzed by assessing their intrinsic differentiation potential into multinucleated 
skeletal myotubes or, under appropriated stimuli, into smooth muscle cells (See 
the specific section “In vitro differentiation assays”). 
Human skeletal muscle cells (SKM, C-12530, Promocell) were used as positive 
control and cultured in the same condition of GRMD MABs.  
Human iPSC-derived mesoangioblast-like cells (HIDEMs) utilized in this study 
were kindly provided by our collaborator in this study Dr. Tedesco from the 
University College of London (London, United Kingdom). HIDEMs were 
generated from DMD patients and healthy donors (HD) induced pluripotent stem 
cells (Kazuki et al., 2010; Tedesco et al., 2012) and maintained in culture as 
previously described (Tedesco et al., 2012; Gerli et al., 2014; Maffioletti et al., 
2015). The DMD patient-derived HIDEMs presented a deletion of exons 4–43 in 
the dystrophin gene, thus representing a valid candidate for the PB-mediated 
transfer of the full-length human dystrophin CDS. Using the same protocol, we 
also independently confirmed the generation of HIDEMs from another DMD 
patient-specific iPSC line that we generated in-house.   
C2C12 myoblasts ((91031101, Sigma-Aldrich, (Yaffe and Saxel, 1977)) were 
cultured, as previously described (Tonlorenzi et al., 2007), in D20 medium 
composed of high glucose DMEM (41965062, Gibco) supplemented with 20% 
FBS, 1% P/S, 1% L-glutamine at 37 °C in a 5% CO2 cell culture incubator. 
HeLa cells, a human cervical cancer cell line (Scherer et al., 1953), were used as 
positive control for a tumor formation assay as described below. The cells were 
cultured in D10 medium composed of high glucose DMEM (41965062, Gibco) 
supplemented with 10% FBS, 1% P/S, 1% L-glutamine at 37 °C in a 5% CO2 cell 
culture incubator. 
 
3.2.  Generation of PB transposon constructs for DMD 
The piggyBac (PB) transposase constructs encoding the non-hyperactive PB 
transposase (mPB) or the hyperactive PB transposase (hyPB) were described 
previously (Di Matteo et al., 2014a). An identical expression plasmid devoid of 
the PB transposase gene (denoted as empty) was used as control. The PB 
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transposon constructs were generated after synthesis of the wild type sequences 
of the PB terminal inverted repeats (IRs; Gene Synthesis, Canada) and cloning 
into the pBluescript II SK (+) plasmid upon digestion with BssHII restriction 
enzyme (Li et al., 2001, 2005b). To produce the transposons PB-SPc-MD1 and 
PB-SPc-MD2, the muscle-specific synthetic promoter SPc5-12 (Li et al., 1999) 
was amplified with primers (forward: 5’-
ATAGCTAGCCAGATCGAGCTCCACCGCGGT-3’; reverse: 5’-
ATAACGCGTGAATTCCTGCAGCCCGGGGG-3’) adding flanking NheI and MluI 
restriction sites, and ligated between the 5’ and 3’ IRs. This intermediate plasmid, 
designated as PB-SPc5-12, was used to insert the codon-usage optimized 
coding DNA sequence (CDS) of human microdystrophin MD1 or MD2 (Koo et al., 
2011b; Athanasopoulos et al., 2011), together with the simian virus 40 (SV40) 
late polyadenylation (pA) signal, after amplification with primers (forward: 5’-
ATAACGCGTGCCACCATGCTGTGGTGGGAG-3’; reverse: 5’-
ATACTCGAGGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCA
-3’) and digestion with MluI and XhoI restriction enzymes. To generate the 
transposon PB-SPc-GFP, the SV40 pA sequence was amplified with primers 
(forward: 5’-ATAACGCGTCAGACATGATAAGATACATTGATG-3’; reverse: 5’-
ATACTCGAGGTTTATTGCAGCTTATAATGGTT-3’) adding flanking MluI and 
XhoI restriction sites, and ligated into the intermediate plasmid PB-SPc5-12. 
Then the transgene copepod green fluorescence protein (GFP, Lonza) was PCR-
amplified (forward: 5’-ATAACTAGTAGCGCTACCGGTCGCCACC-3’; reverse: 5’-
ATAACGCGTAGATCTGGCGAAGGCGATGGG-3’) flanked by SpeI and MluI 
restriction sites and cloned between the SPc5-12 promoter and the SV40 pA 
signal. To produce the transposon PB-Pgk-GFP, the PCR primers (forward: 5’-
GTACGGCTAGCGTTAACAATTCTACCGGGTAGG-3’, reverse: 5’-
GACGTAGCGCTATGCAGGTCGAAAGGC-3’) containing NheI and Eco47III 
restriction sites were used to amplify the constitutive phophoglycerate kinase 1 
(Pgk, Addgene) promoter and cloned it into the correspondent sites of PB-SPc5-
12, in order to replace SPc5-12 promoter. For the construction of the large size 
transposon PB-SPc-DYS-Pgk-GFP, the following fragment SPc5-12 promoter-
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KpnI-NheI-SgsI-SV40 pA signal has been synthesized (DNA cloning, Germany) 
adding flanking restriction sites NotI and XhoI, and inserted between the 5’ and 3’ 
PB IRs of the pBluescript II SK (+) plasmid. This allowed the ligation of the codon 
usage optimized full-length human dystrophin CDS (Jarmin et al, unpublished) 
upon digestion first with KpnI and NheI, and then with NheI and SgsI restriction 
enzymes. The GFP reporter gene was then inserted together with the Pgk 
promoter and the SV40 pA signal downstream the full-length human dystrophin 
expression cassette using HpaI and XhoI restriction sites. The entire expression 
cassette of all the PB transposons was flanked with loxP sites allowing for a 
possible subsequent excision by CRE recombinase (Di Matteo et al., 2012; 
VandenDriessche et al., 2009). The sequences of the constructs involving PCR-
based cloning were confirmed by DNA sequencing. 
 
3.3.  Cell electroporation 
Cells were electroporated with the Amaxa Nucleofector II (Lonza). For GRMD 
MABs and DMD HIDEMs, the Human MSC Nucleofector Kit was used with 
respectively the program U-23 and C-17. For C2C12 myoblasts, the Cell Line 
Nucleofector Kit V and the program B-32 were applied.  
Transfections were optimized to obtain good efficiency with low levels of toxicity, 
modifying the amount of plasmids used and the transposase DNA: transposon 
DNA ratio. Briefly, cells were trypsinized (Trypsin-EDTA 1X, 25300-054, Gibco), 
washed in phosphate-buffered saline (PBS, 14190169, Gibco) and counted. One 
million cells were electroporated with the indicated concentration of transposase 
DNA: transposon DNA and subsequently seeded in a single well of a 6-well 
multidish (Nunc). The day after, the medium was refreshed. When the cells were 
transfected with PB transposons coding for the GFP, the expression of the 
reporter was monitored at different time point post-electroporation (post-EP) by 
live cell imaging using fluorescence microscopy (IX81,Olympus; DMI6000B, 
Leica). 
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3.4.  Flow cytometry and FACS 
Expression of CD44, CD34 and CD45 markers on GRMD MABs was assessed 
after the cells were trypsinized, washed in PBS and incubated with specific anti-
dog fluorochrome-conjugated monoclonal antibodies for 1 hour at 4 °C: anti-
CD44-APC (FAB5449A, R&D Systems), anti-CD34-PE (559369, BD 
Biosciences), anti-CD45-RPE (MCA1042PE, AbD Serotec). Cells were 
subsequently washed with PBS, fixed in 2% paraformaldehyde (PFA, Sigma-
Aldrich) and resuspended in PBS supplemented with 1% FBS and 2mM EDTA 
(15575020, Invitrogen). Cytofluorimetric analysis was performed using a 
FACSCanto flow cytometer (Becton Dickinson). 
When GRMD MABs, DMD HIDEMs and C2C12 were transfected with PB 
transposons coding for the GFP, the transfection efficiency was assessed by the 
detection of the percentage of GFP positive cells post-EP by flow cytometer 
(FACSCanto, Becton Dickinson; CyAn ADP, Beckman Coulter). Transfected cells 
were monitored at different time points for 30 to 45 days post-EP to assess 
transposition efficiency. Where indicated, the GFP positive populations were 
enriched by cell sorting using a BD FACSAria III cell sorter (Becton Dickinson). 
Briefly, cells were trypsinized, washed in PBS, counted and resuspended in PBS 
supplemented with 1% FBS and 2mM EDTA (15575020, Invitrogen). Analysis of 
the acquired data was performed with Summit (Beckman Coulter) or BD 
FACSDiva (Becton Dickinson). 
 
3.5.  In vitro differentiation assays  
The ability of MABs, HIDEMs, SKM cells and C2C12 cells to differentiate into 
skeletal muscle was assessed in vitro by exposing the cells, upon reaching 80% 
of confluence, to a specific differentiation medium composed of DMEM 
supplemented with 2% horse serum (ECS0090L, Euroclone), 1% P/S, 1% L-
glutamine for 4 to 10 days (Tonlorenzi et al., 2007). For this assay MABs, 
HIDEMs and SKM cells were seeded onto matrigel (356230, Becton Dickinson) 
coated dishes while C2C12 cells were induced to differentiate on a 6-well 
multidish (Nunc). To induce myogenic differentiation of MABs at late passages 
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(i.e. passage P15-18) and of HIDEMs, cells were transduced with lentiviral 
vectors containing a tamoxifen-inducible MyoD-ER (MyoD-ER(T) LV vector) 
(Kimura et al., 2010; Tedesco et al., 2012; Maffioletti et al., 2015). Lentiviral 
vector titration was calculated using the p24 assay (QuickTiter Lentivirus 
Quantitation Kit, Cellbiolabs). Briefly, 0.14x106 cells were transduced with 10 or 
50 multiplicities of infection (MOI) of MyoD-ER(T) LV vector in 1 ml of growth 
medium and incubated for 12 hours at 37 °C in a 5% CO2, 3% O2 cell culture 
incubator. The medium was subsequently changed and cells were maintained in 
culture for 2 to 3 passages. The in vitro myogenic differentiation assay was 
performed seeding the cells onto matrigel (BD Biosciences) coated dishes, 
followed by the exposure to 1 μM 4-hydroxy-tamoxifen (Sigma-Aldrich) in the 
growth medium for 24 hours, upon confluence. This was replaced by 
differentiation medium supplemented with 1 μ M 4-hydroxy-tamoxifen for 
additional 24 hours. Half of the medium was replaced with fresh differentiation 
medium every other day for 5-7 days. Immunofluorescence (IF) staining for 
myosin heavy chain (MyHC) was performed to confirm terminal myogenic 
differentiation (see specific section for “Immunohistochemistry”). 
Differentiation of GRMD MABs in smooth muscle-like cells was induced by 
treating the cells for 10 days with differentiation medium supplemented with 5 
ng/ml transforming growth factor β1 (TGF-β1, 100-21, Peprotech) (Ross et al., 
2006). Smooth muscle differentiation was confirmed by IF staining for α-smooth 
muscle actin (see specific section for “Immunohistochemistry”). 
 
3.6.  RNA expression analysis 
Total RNA from cells was extracted (RNeasy Mini Kit, QIAGEN) and reverse 
transcribed using a cDNA synthesis kit (SuperScript ΙΙΙ  First-Strand 
synthesis system for RT-PCR kit, Invitrogen). For Reverse transcription-PCR 
(RT-PCR), cDNA was amplified on a PCR thermocycler (Biorad) with GoTaq 
DNA Polymerase (M3005, Promega). Amplifications were performed using the 
primers listed Table 4, at the annealing temperature of 60 °C for 29 cycles on 
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GRMD MABs, 25-28 cycles on DMD HIDEMs and 25 cycles on C2C12 cells. The 
amplified fragments were resolved by electrophoresis on a 2% agarose gel. For 
quantitative RT-PCR (qRT-PCR), cDNA was amplified on a Step-One Real-Time 
PCR System (Applied Biosystems) with SYBR green PCR Master mix (4309155, 
Applied Biosystem). The mRNA levels of the transgene of interest were 
determined by qRT-PCR using the primers described in Table 5. The semi-
quantitative RT-PCR for the characterization of GRMD MABs was performed by 
using the primers listed in Table 6 at the annealing temperature of 60 °C for 33 
cycles. Amplicons were then resolved by electrophoresis on a 2% agarose gel. 
Data were normalized to the Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) housekeeping gene or to the MyHC gene specific for the skeletal 
muscle differentiation, as specified. The expression levels of the selected 
transgene was calculated using a standard Δ Δ Ct method (Livak and 
Schmittgen, 2001). 
 
Primer Sequence Amplicon size 
N-terminus   221 bp 
huDys_co seq 1 5’-GGGCCTGATCTGGAACATCATC-3’   
huDys_SO f1 R2 5’-CGAACAGGTCGGGTCTGTGGC-3’   
Central domain   222 bp 
huDys_SO f5 F 5’-CTTCGAGGATCTGTTCAAGCAGG-3’   
huDysSO f5 R  5’-CTGTCGAATCTGCCCTGCCGG-3’   
C-terminus  228 bp 
huDys_SO f5 F2 5’-CCGAGTACGACAGACTGAAG-3’   
huDys_SO f7 R2 5’-CCAGCAGCTGTCTGAGTCTG-3’   
 
Table 4. List of primers utilized for RT-PCR. Listed in the table the RT-PCR primers 
used for this study with the corresponding expected size of the amplicons. 
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Primer Sequence Amplicon size 
huMD1co/ huMD2co 5’-GTGCCCTACTACATCAA-3’ 174 bp 
  5’-AGGTTGTGCTGGTCCA-3’   
huDYSco 5’-GGGCGACAACATGGAGACCGA-3’ 263 bp 
  5’- AGGGCGTGCACTCTGGTGCT-3’   
DYS 5’-GCAAGAGCAACAAAGTGGCCTA-3’ 128 bp 
  5’-AGCTTCTTCCAGCGTCCCTCA-3’   
GFP 5’-GAGCACCAAAGGCGCCCTGA-3’ 143 bp 
  5’-CGGGTGTTGGTGTAGCCGCC-3’   
MyHC 5’-GCATCGAGCTCATCGAGAAG-3’ 102 bp 
  5’-CATACAGCTTGTTCTTGAAGGAGG-3’   
GAPDH 5’-TCAAGAAGGTGGTGAAGCAGG-3’ 168 bp 
  5’-ACCAGGAAATGAGCTTGACAAA-3’   
 
Table 5. List of primers utilized for qRT-PCR. Listed in the table the qRT-PCR primers 
used for this study with the corresponding expected size of the amplicons. 
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Primer Sequence Amplicon size 
PAX7 5’-CAGGCCGACTTCTCCATCTC-3’ 288 bp 
  5’-GAGTCCCAGCACAGCAGAAT-3’   
MYF5 5’-TCCGAGTACTTCTACGACGG-3’ 368 bp 
  5’-AGGCTCTCGATGTAGCGGAT-3’   
CD56 5’-TCTCTCCCACCGACCATCAT-3’ 328 bp 
  5’-GTTCCCCCTCCTTTGTCCAG-3’   
Desmin 5’-ATGAGCCAGGCCTACTCGTC-3’ 378 bp 
  5’-GCGCACCTTCTCGATGTAGT-3’   
NG2 5’-GTCCGACGGGCGGCACCAGG-3’ 340 bp 
  5’-CACAGGCCCTGCCTCCACGG-3’   
PDGFRβ 5’-GCCAGCTCCTGTCCTCAAAG-3’ 385 bp 
  5’-GAGTTCCTCAGGGTCAACCG-3’   
GAPDH 5’-TCAAGAAGGTGGTGAAGCAGG-3’ 168 bp 
  5’-ACCAGGAAATGAGCTTGACAAA-3’   
 
Table 6. List of primers utilized for semi-quantitative RT-PCR. Listed in the table the 
primers for semi-quantitative RT-PCR utilized in this study for the characterization of the 
GRMD MABs. 
 
3.7.  Immunohistochemistry 
Immunofluorescence (IF) assays were performed on cells fixed with 4% 
paraformaldehyde (Sigma-Aldrich) at room temperature (RT) for 10 minutes or 
directly on sections from processed tissues. After permeabilization in PBS 
containing 0.2% Triton X-100 (T9284, Sigma-Aldrich) and 1% bovine serum 
albumin (BSA, A8022, Sigma-Aldrich) at RT for 30 minutes, the non-specific 
binding sites were blocked using 10% donkey serum (D9663, Sigma-Aldrich) at 
RT for 30 minutes. Samples were subsequently incubated overnight at 4 °C with 
the following primary antibodies: rabbit anti-turboGFP (AB513; Evrogen), mouse 
anti-dystrophin (NCL-DYS1, NCL-DYS2, NCL-DYS3; Novocastra), mouse anti-
myosin heavy chain (MyHC MF20; Developmental Studies Hybridoma Bank, 
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USA), rabbit anti-myosin (476126; Calbiochem), rabbit anti-human lamin A/C 
(ab108595, Abcam), rat anti-laminin (sc33709; Santa Cruz Biotechnology), 
mouse anti-myogenin (F5D; Developmental Studies Hybridoma Bank, USA), 
rabbit anti-MyoD (M-318; Santa Cruz), mouse anti-sarcomeric α -actinin 
(ab9465; Abcam), mouse anti-α-smooth muscle actin (A2547; Sigma-Aldrich). 
After incubation, samples were washed with PBS and incubated with the 
appropriate 488, 546, 594 or 647 fluorochrome-conjugated secondary antibodies 
(Life Technologies) together with Hoechst 33342 for nucleic acid staining (B2261; 
Sigma-Aldrich) for 1 hour at RT in PBS containing 0.2% Triton X-100. After 
washing with PBS, slides were mounted using fluorescent mounting medium 
(Dako) and examined by fluorescence microscopy (DMI6000B, Leica; Eclipse80i, 
Nikon). Images were analyzed using ImageJ software (NIH; 
http://rsbweb.nih.gov/ij/download.html).  
 
3.8.  Western blot analysis 
The expression of the full-length human dystrophin protein mediated by the PB 
transposon was assessed by Western Blot analysis. Upon myogenic 
differentiation in vitro, cells were washed 2 times with cold PBS and lysed in 
RIPA buffer (50 mM Tris pH 8, 150 mM NaCl, 1% Triton X‐100, 0.5% sodium 
deoxycholate, and 0.1% sodium dodecyl sulfate (SDS)) supplemented with a 
protease inhibitor cocktail (11836145001, Roche) for 30 minutes on ice. Clear 
cell lysates were obtained by centrifugation at 13200 rpm for 15 minutes at 4 °C 
and total proteins were quantified by BCA protein assay kit (23227, 
ThermoFisher). Equal amounts of total proteins per sample were separated by 
SDS-PAGE on 3-8% Tris-Acetate Gel (EA0378BOX, Invitrogen). After 
electrophoresis, the gel was transferred to a 0,2 μm nitrocellulose membrane 
using the Trans-Blot turbo transfer system (Bio-Rad). To prevent the nonspecific 
binding of the antibodies, the membrane was incubated in TBST buffer 5% milk 
for 1 hour. The membrane was then probed with the following non-conjugated 
primary antibodies and incubated overnight: mouse anti-dystrophin DYS1 and 
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DYS2 (NCL-DYS1 and NCL-DYS2, mouse anti-dystrophin, Novocastra), mouse 
anti-human dystrophin (NCL-DYS3, Novocastra) and mouse anti-myosin heavy 
chain (MyHC MF20, Developmental Studies Hybridoma Bank, USA). An HRP-
conjugated goat anti-mouse (sc-2005, Santa Cruz) was used as secondary 
antibody. To detect a housekeeping protein, the HRP-conjugated anti-beta 
tubulin (ab21058, Abcam) was used. The acquisition of the signal was performed 
by Enhanced Chemiluminescent Reagents (ECL, Invitrogen) or West Femto 
(Thermo Scientific), according to the manufacturer’s instructions. SKM cells 
differentiated into skeletal muscle in vitro were used as positive control. 
 
3.9. Transposon genome copy number quantification 
The number of copies of PB transposons integrated per cell (diploid genome) 
was calculated by performing a qPCR analysis on genomic DNA extracted from 
the cells (DNeasy Blood & Tissue Kit, Qiagen). Primers specific for the 5’ 
inverted repeat region (5’IR) of the PB transposon were used, as previously 
described (Di Matteo et al., 2014a). The standard curve was determined by a 
known copy number of the corresponding PB transposon plasmid. 
 
3.10. Mice 
Immunodeficient dystrophic scid/mdx mice were kindly provided by Dr. Torrente 
from the University of Milan (Milan, Italy; (Farini et al., 2007)). Nude mice 
(Crl:NU-Foxn1nu strain) were purchased from Charles Rivers. All the animals 
used for this study were housed in specific pathogen free (SPF) condition at the 
KU Leuven facility (Leuven, Belgium) or at UCL facility (London, United 
Kingdom). The experimental procedures were approved by the Institutional 
Animal Care and Research Advisory Committee of KU Leuven as well as by the 
UCL ethical committee, in accordance to the Home Office regulations (ASPA 
1986). The use of animals has been rationalized by implementing the 3Rs 
(Reduction, Refinement, Replacement). 
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3.11. Intra-muscular transplantation  
Adult age matched scid/mdx mice were used for the intra-muscular 
transplantation experiments (n= 6). As previously reported (Tedesco et al., 2012; 
Gerli et al., 2014; Maffioletti et al., 2015), mice were treated with 3.5 μl/g of 10 
mg/ml tamoxifen (liposoluble formulation, T5648, Sigma-Aldrich) via intra-
peritoneal injection during the three days prior to- and post-transplantation, once 
a day.  The cells were pre-treated with 1 μM 4-hydroxy-tamoxifen (aqueous 
formulation, H7904, Sigma-Aldrich) in the growth medium overnight prior to the 
transplantation. The cells were then trypsinized, washed in PBS, filtered with a 
40 μm cell strainer to avoid possible clusters (352340, Corning), centrifuged at 
232 x g for 5 min and resuspended in PBS at the concentration of 1x106 cells/30 
µl. Injection of 30 µl of cell suspension was performed into the tibialis anterior 
and the gastrocnemius muscles with a 30G needle syringe. Muscles injected with 
30 µl of PBS were used as negative controls. Animals were sacrificed 1 and 3 
weeks after the intra-muscular transplantation. Treated and control muscles were 
harvested, dehydrated in liquid nitrogen-cooled isopentane for one minute, snap-
frozen in liquid nitrogen for two additional minutes and stored at 80 °C. The 
tissue samples were processed with the cryostat (CM1850, Leica) to obtain 7 µm 
thick sections for immunofluorescence staining. Serial sections were also 
collected into a 1.5 ml tubes to perform molecular biology assays. 
 
3.12. Tumor formation assay 
To assess the safety of the cell lines used in this study for in vivo applications, a 
tumor formation assay was performed. DMD HIDEMs co-transfected with hyPB 
transposase and PB-SPc-DYS-Pgk-GFP transposon (n= 8) or PB-Pgk-GFP 
transposon (n= 8) and transduced with MyoD-ER(T) LV vector were injected 
subcutaneously in immunodeficient nude mice (Crl:NU-Foxn1nu strain). As 
controls, untransfected DMD HIDEMs with and without MyoD-ER(T) LV vector 
infection (n= 3 and n= 2, respectively) were utilized. HeLa cells, a tumorigenic 
human cell line, were injected as a positive control (n= 2). Briefly, the cells were 
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trypsinized, washed in PBS, filtered with a 40 μm cell strainer, centrifuged at 
232 x g for 5 min and resuspended in PBS at the concentration of 2x106 
cells/100 µl. After the subcutaneous injection, the mice were then inspected 
biweekly for 4 months. At the end of the assay, animals were sacrificed and 
necropsy was operated to confirm the absence of tumor masses. 
 
3.13. Statistical analysis 
Data were presented as mean ± standard deviation (SD) or standard error of the 
mean (SEM). Comparison between groups was performed by using two-tailed 
unpaired Student’s t-test or two-way ANOVA (Bonferroni’s multiple comparison 
test). 
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Chapter 4 
 
4. Results 
 
The data of the following section 4.1 are published in: 
Loperfido M, Jarmin S, Dastidar S, Di Matteo M, Perini I, Moore M, Nair N, Samara-
Kuko E, Athanasopoulos T, Tedesco FS, Dickson G#, Sampaolesi M#, VandenDriessche 
T#, Chuah MK#,*. piggyBac transposons expressing full-length human dystrophin enable 
genetic correction of dystrophic mesoangioblasts. Nucleic Acids Research 2016 Jan 
29;44(2):744-60. doi: 10.1093/nar/gkv1464. Epub 2015 Dec 17. 
# These authors share joint senior authorship; *Corresponding author. 
 
4.1. Genetic correction of dystrophic mesoangioblasts 
using piggyBac transposons expressing full-length human 
dystrophin CDS 
 
4.1.1. Generation of PB transposons coding for human dystrophin 
CDS 
We generated PB transposons designed to express the full-length or truncated 
versions of a codon-optimized human dystrophin CDS (Athanasopoulos et al., 
2011) from the muscle-specific synthetic promoter SPc5-12 (346 bp) (Li et al., 
1999; Koo et al., 2011b; Rincon et al., 2014) (Figure 6). The simian virus 40 
(SV40) late polyadenylation (pA) signal was incorporated as transcription 
terminator in all the expression cassettes. Given the large cargo that PB 
transposons could accommodate (Ding et al., 2005; Li et al., 2011), we 
generated a large-size transposon named PB-SPc-DYS-Pgk-GFP coding for the 
full-length human dystrophin CDS (huDYSco; size: 11.1 Kb) driven by the 
synthetic SPc5-12 promoter, and a GFP reporter transgene driven by the 
constitutive phophoglycerate kinase 1 (Pgk) promoter (transposon size: 17 Kb) 
(Figure 6A). PB-SPc-MD1 (Figure 6B) and PB-SPc-MD2 (Figure 6C) 
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transposons encoded respectively for two different codon usage-optimized 
microdystrophin CDS: huMD1co (size: 3.6 Kb) and huMD2co (size: 4 Kb) 
whereby the C-terminal domain was deleted in huMD1co (Koo et al., 2011b) 
(transposon size: 8.2 Kb and 8.6 Kb, respectively). As controls, PB-SPc-GFP 
(Figure 6D) and PB-Pgk-GFP  (Figure 6E) transposons carried only the copepod 
GFP sequence under the control of the SPc5-12 or the constitutive Pgk promoter 
(transposon size: 5.2 Kb and 5.4 Kb, respectively). The transposase plasmids 
included the mPB expression plasmid encoding the murine codon-optimized non-
hyperactive PB transposase (Figure 6F; (Cadiñanos and Bradley, 2007)) and the 
hyPB expression plasmid encoding the murine codon-optimized hyperactive PB 
transposase (Figure 6G; (Yusa et al., 2011)). The transposases were driven by 
the cytomegalovirus (CMV) promoter cloned upstream of a β-globin intron (βGI) 
sequence, and were followed by a bovine growth hormone polyA (bghpA) signal. 
An empty plasmid that contained an identical expression cassette, but devoid of 
transposase (Figure 6H), was employed as control (Di Matteo et al., 2014a). 
 93 
 
Figure 6. Schematic representation of PB transposon and PB transposase 
constructs. (A) PB-SPc-DYS-Pgk-GFP transposon encoding the codon optimized full-
length human dystrophin CDS (huDYSco; (Athanasopoulos et al., 2011)) is represented 
as in its four major structural domains: N-terminal domain (N), a central rod domain, a 
cysteine-rich (CR) domain and a distal C-terminal domain (C). The central rod domain 
contains 24 triple-helix rod repeats and four hinges (H1–H4). The full-length human 
dystrophin CDS is driven by the muscle-specific synthetic promoter SPc5-12 (Li et al., 
1999). Downstream, the sequence of a copepod GFP has been cloned as a reporter 
driven by the Pgk promoter. (B) PB-SPc-MD1 transposon and (C) PB-SPc-MD2 
transposon encode respectively for huMD1co and huMD2co CDS; these are two 
different codon optimized human microdystrophins that lack the original sequence of rod 
repeats 4-23 and differ for the presence of the C-terminal domain sequence in MD2 
(Athanasopoulos et al., 2011). This extra sequence has been shown to improve the 
efficiency on restoring muscle function in dystrophic mdx mice (Koo et al., 2011a). Both 
the microdystrophins are driven by SPc5-12 promoter. (D) PB-SPc-GFP and (E) PB-
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Pgk-GFP are transposons that accommodate the GFP sequence respectively under the 
SPc5-12 or the Pgk promoter. All the transposon constructs are flanked by wild-type 
inverted repeats (IR) and loxP sites (loxP). All the transgenes in the transposon 
constructs are followed by the simian virus 40 late polyadenylation signal (pA). (F) The 
mPB transposase and (G) the hyPB transposase are driven by the cytomegalovirus 
(CMV) promoter cloned upstream of a β-globin intron (βGI). The seven hyperactive 
mutations that differ the hyPB transposase sequence from the mPB are indicated as 
seven different symbols in the hyPB construct. A bovine growth hormone polyA (bghpA) 
signal is cloned downstream of the transposase sequences. (H) The empty control 
plasmid contains a multiple cloning site (MCS) between the CMV promotor and the 
bghpA. 
  
4.1.2. Expression of human microdystrophins after PB-mediated 
transposition in C2C12 myoblasts 
We first tested the functionality of the PB-SPc-GFP, PB-SPc-MD1 and PB-SPc-
MD2 transposons since they are smaller in size and therefore easier to transfer 
into the target cells. C2C12 cells, a murine myoblast cell line (Yaffe and Saxel, 
1977), were co-transfected by electroporation with the PB-SPc-GFP transposon 
and the mPB  transposase-encoding construct (ratio of 1.26 pmol transposase 
DNA: 3.48 pmol transposon DNA). In parallel, PB-SPc-MD1 and PB-SPc-MD2 
transposons were electroporated under the same conditions. To determine the 
transfection efficiency of mPB transposase and PB-SPc-GFP transposon, FACS 
analysis was performed 48 hours post-electroporation (EP), showing 26±4% 
GFP+ cells which remained relatively stable (24±4% GFP+ cells at 72 hours 
post-EP; not statistically significant) (Figure 7A, left panel). As control, the empty 
expression plasmid- devoid of mPB transposase gene- was electroporated with 
the PB-SPc-GFP transposon resulting initially in comparable transfection 
efficiencies at 48 hours (17±1% GFP+ cells). However, in contrast to when the 
mPB expression vector was employed, the percentage of GFP+ transfected cells 
gradually declined at 72 hours post-EP, consistent with the loss of non-integrated 
PB-SPc-GFP plasmids in the rapidly dividing C2C12 cells (9±1% GFP+ cells; p≤ 
0.01). Similarly, the mean fluorescent intensity (MFI) was sustained when the 
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PB-SPc-GFP transposon was co-transfected with mPB and significantly different 
from the controls (p≤ 0.001) (Figure 7A, right panel). These FACS data were 
confirmed by live cell imaging (Figure 7B). 
Subsequently, we assessed whether C2C12 cells transposed with the PB 
transposons retained their ability to differentiate into skeletal muscle and whether 
expression of the GFP and microdystrophins MD1 and MD2, encoded by the 
transposons, was sustained upon differentiation. Four days after incubation with 
the differentiation medium (corresponding to 10 days post-EP), multinucleated 
myotubes were observed. The transcription levels of GFP (Figure 7C) and the 
human microdystrophins MD1 and MD2  (Figure 7D) were detectable by qRT-
PCR and showed a significantly increased expression upon differentiation (p≤ 
0.01 for GFP, p≤ 0.001 for the microdystrophins). This confirmed the muscle-
specificity of the synthetic SPc5-12 promoter, consistent with its up-regulation 
upon myogenic differentiation. The transcript levels of the microdystrophins MD1 
and MD2 in the differentiated C2C12 cells were comparable to the level of 
human dystrophin transcripts in differentiated human skeletal muscle (SKM) cells 
(Figure 7D). In contrast, we were not able to detect any GFP expression from 
differentiated C2C12 cells that were co-transfected with the empty plasmid and 
the PB-SPc-GFP transposon (Figure 7C). This indicates that transposition was a 
prerequisite to ensure stable GFP transcript levels. Immunofluorescence (IF) 
staining independently confirmed GFP (Figure 7E) and human microdystrophin 
MD1 and MD2 expression (Figure 7F) respectively in the myosin heavy chain 
(MyHC) and myosin positive myotubes, derived from the transposed C2C12 
cells. The percentage of myotubes positive for GFP, MD1 or MD2 was 
determined by counting the nuclei within these myotubes divided by the total 
number of nuclei within the MyHC positive myotubes (68±6% for GFP; 65±2% for 
MD1 and 66±2% for MD2, respectively). Collectively, these results demonstrate 
that the PB transposon system is well suited to achieve sustained muscle-
specific expression of human microdystrophins upon transposition in 
differentiated myogenic cells. The validation of the PB transposon system for the 
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delivery of the truncated human dystrophins paves the way towards the use of 
the full-length human dystrophin. 
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Figure 7. PB-mediated expression of MD1 and MD2 in C2C12 myoblasts. (A) The 
bar graphs show respectively the percentage of GFP+ (left) and the mean fluorescence 
intensity (MFI; right) of C2C12 cells at 48 and 72 h post-electroporation (EP) with the 
PB-SPc-GFP transposon when co-transfected with the mPB transposase or the empty 
plasmid (ratio of 1.26 pmol transposase DNA: 3.48 pmol transposon DNA). 
Untransfected cells are also shown. Shown are mean±SEM of three independent 
biological replicates; two-tailed unpaired Student’s t-test (***P ≤ 0.001; **P ≤ 0.01; *P ≤ 
0.05; ns: not significant). (B) Live cell imaging showing the GFP expression of the 
conditions described in (A) at 24, 48 and 72 h post-EP (UNTR: untransfected; scale bar 
100 µm). (C) The bar graph depicts the GFP transcript levels detected by qRT-PCR in 
PB-transposed C2C12 myoblasts in proliferation (white bars) and myotubes in 
differentiation (black bars). (D) The bar graph depicts the MD1 and MD2 transcript levels 
detected by qRT-PCR in PB-transposed C2C12 myoblasts in proliferation (white bars) 
and myotubes in differentiation (black bars). (C,D) In both the graphs, the transcript 
levels of the human dystrophin from the human skeletal muscle (SKM) cells and 
myotubes were used as positive control. Values were normalized for the myosin heavy 
chain (MyHC) and shown as relative expression. Shown are mean±SEM of triplicate 
qRT-PCR analyses performed for three independent biological replicates; two-tailed 
unpaired Student’s t-test (***P ≤ 0.001; **P ≤ 0.01; ns: not significant). (E) 
Immunofluorescence staining to detect the co-localized expression of the GFP (in green) 
and the MyHC (in red) in C2C12 cells differentiatiated in skeletal muscle in vitro upon 
transposition with hyPB transposase and PB-SPc-GFP transposon. The condition empty 
plasmid + PB-SPc-GFP is shown as negative control.  (F) Immunofluorescence staining 
to detect the co-localized expression of the human microdystrophin MD1 or MD2 (in 
green) and the myosin (in red) in C2C12 cells differentiatiated in skeletal muscle in vitro 
upon transposition with hyPB transposase and PB-SPc-MD1 or PB-SPc-MD2 
transposon. Untransfected cells are also shown as negative controls. The mouse anti-
human dystrophin NCL-DYS3 antibody was used. The nuclei were stained with Hoechst 
(Scale bar 100 µm). 
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4.1.3. Increased transposition in C2C12 myoblasts with the 
hyperactive PB transposase and the PB transposon encoding 
the full-length human dystrophin CDS 
Different research groups, including ours, have shown that the hyPB transposase 
resulted in increased transposition as compared to the mPB transposase (Di 
Matteo et al., 2014a; Burnight et al., 2012; Doherty et al., 2012; Yusa et al., 
2011). In line with these results, we therefore assessed the transposition 
efficiency of hyPB transposase in a head-to-head comparison with the mPB 
transposase, along with the large-size transposon PB-SPc-DYS-Pgk-GFP (17 
Kb) in C2C12 myoblasts. This represents the first attempt in delivering the full-
length dystrophin CDS by the PB transposon system. The mPB or hyPB-
encoding expression constructs were electroporated together with PB-SPc-DYS-
Pgk-GFP transposon in C2C12 myoblasts (ratio of 0.32 pmol transposase DNA: 
0.87 pmol transposon DNA). Controls were transfected with the empty 
expression plasmid devoid of any PB transposase and with the PB-SPc-DYS-
Pgk-GFP transposon. Due to the large size transposon, the percentage of GFP 
positive C2C12 myoblasts at 4 days post-EP resulted to be 4±0.5% after co-
transfection with the hyPB transposase and 2±0.5% after co-transfection with the 
mPB transposase. The GFP positive populations were then enriched by FACS 
sorting and monitored at different time points by FACS analysis and fluorescence 
microscopy (Figure 8A, 8B). At 30 days post sorting, 78±3% of the cells 
transfected with the hyPB transposase were GFP positive, showing a statistically 
significant (p≤ 0.01) higher percentage compared to when the mPB was 
employed (63±3% GFP positive cells). Consistently, a statistically significant 
difference in MFI (p≤ 0.001) was detected by FACS when the hyPB was used 
compared to the mPB (Figure 8B). 
We subsequently assessed whether C2C12 cells transposed with the hyPB 
transposase and the large-size transposon PB-SPc-DYS-Pgk-GFP expressed 
the human full-length dystrophin and retained their ability to differentiate into 
skeletal muscle. Four days after incubation with the differentiation medium 
(corresponding to 24 days post-EP), multinucleated myotubes were observed. 
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The transcription levels of the full-length human dystrophin were detectable by 
qRT-PCR and showed a significant increase in expression in C2C12 cells 
differentiated in myotubes compared to when the cells were retained in a 
proliferative, non-differentiated state (p≤ 0.001; Figure 9A). This is consistent with 
our previous results (Figures 6C, 6D) and confirms the muscle-specificity of the 
synthetic SPc5-12 promoter and its up-regulation upon myogenic differentiation. 
To demonstrate that the full-length human dystrophin CDS expresses a full-
length transcript, a reverse transcriptase PCR (RT-PCR) was first performed 
using three different primer pairs that respectively amplify three different regions 
of the full-length dystrophin transcript, including the N-terminal, central and C-
terminal sequences (Table 4). The three bands corresponding to these 
respective amplified regions were detected in differentiated C2C12 myoblasts 
that had undergone transposition after transfection with the hyPB transposase 
and the PB-SPc-DYS-Pgk-GFP transposon constructs (Figure 9B). In contrast, 
these specific PCR bands were absent in the untreated differentiated C2C12 
cells or in differentiated C2C12 cells co-transfected with the PB-SPc-DYS-Pgk-
GFP transposon and an empty expression plasmid without transposase (Figure 
9B). 
Western blot analysis subsequently confirmed expression of the full-length 
human dystrophin protein (427 kDa) in myotubes derived from C2C12 cells that 
had undergone transposition after transfection with the hyPB transposase and 
the PB-SPc-DYS-Pgk-GFP transposon constructs (Figure 9C). Dystrophin 
expression in these myotubes coincided with GFP and myosin expression, as 
confirmed by immunofluorescence assay (Figure 9D, 9E).  Similarly, Western 
blot analysis demonstrated expression of the full-length human dystrophin protein 
(427 kDa) in differentiated normal human skeletal muscle cells (SKM, Figure 9C), 
whereas no dystrophin expression was apparent in non-transfected differentiated 
C2C12 cells or differentiated C2C12 cells co-transfected with the PB-SPc-DYS-
Pgk-GFP transposon and an empty expression plasmid without transposase 
(Figure 9C). 
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Collectively, these results justify the use of hyperactive PB transposase to 
achieve a stable integration of the PB transposon coding for the full-length 
human dystrophin and a sustained expression of the protein in differentiated 
myogenic cells. 
 
 
Figure 8. Validation of the use of hyPB transposase in C2C12 myoblasts. (A) Live 
cell imaging depicting the GFP expression in C2C12 myoblasts at different time points 
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after sorting, when the large-size transposon PB-SPc-DYS-Pgk-GFP is co-transfected 
with hyPB or mPB transposase (Scale bar 100 µm). (B) Graphs representing the 
comparison between hyPB and mPB transposases in terms of percentage of GFP+ 
population (graph above) and mean fluorescence intensity (MFI, graph below). The 
GFP+ populations were enriched by FACS at 4 days post-EP and monitored for the GFP 
expression in the next 30 days after the sorting. The higher efficiency of the hyPB 
transposase over the mPB transposase was assessed at the concentration of 0.32 pmol 
transposase DNA: 0.87 pmol transposon DNA. Results were presented as mean±SD of 
three independent biological replicates; two-way ANOVA (Bonferroni’s multiple 
comparison test); ***P ≤ 0.001; **P ≤ 0.01. 
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Figure 9. Human full-length dystrophin expression in PB-transposed C2C12 
myoblast-derived differentiated myotubes. (A) The transcript levels of the full-length 
human dystrophin (black bars) and the GFP (white bars) were detected by qRT-PCR in 
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C2C12 cells transposed with hyPB + PB-SPc-DYSPgk-GFP, while in proliferation or in 
differentiated myotubes (D: differentiated sample). Results were presented as 
mean±SEM of triplicate qRT-PCR analyses performed for three independent biological 
replicates; two-tailed unpaired Student’s t-test (***P≤0.001; ns: not significant). (B) RT-
PCR showing expression of full-length human dystrophin transcript in myotubes derived 
from C2C12 cells that had undergone transposition after co-transfection with hyPB and 
PB-SPc-DYS-Pgk-GFP. Three different primer pairs were used that recognize 
respectively (1) the N-terminal, (2) a central region and (3) the C-terminal sequences, 
yielding amplicons of 221 bp, 222 bp and 228 bp, respectively. A schematic 
representation of the PCR primers relative to the different regions of the dystrophin 
transcript is depicted. Human skeletal muscle cells (SKM) differentiated in myotubes 
were used as a positive control; the primer pairs DYS listed in Table 5 have been used 
for this sample. Negative controls included untreated differentiated C2C12 cells 
(designated as C2C12) or differentiated C2C12 cells co-transfected with the PB-SPc-
DYS-Pgk-GFP transposon and an empty expression plasmid without transposase 
(designated as Empty). L: 50 bp ladder. (C) Western blot analysis demonstrating 
expression of the full-length human dystrophin protein (427 kDa) in myotubes derived 
from C2C12 cells that had undergone transposition after cotransfection with hyPB and 
PB-SPc-DYS-Pgk-GFP. The antibody NCL-DYS3 was used to detect the human 
dystrophin. Non-transfected differentiated C2C12 cells or differentiated C2C12 cells co-
transfected with the PB-SPc-DYS-Pgk-GFP transposon and an empty expression 
plasmid without transposase were included as negative controls. Normal human skeletal 
muscle cells were used as positive control. In vitro skeletal muscle differentiation was 
confirmed for all the samples by the expression of the MyHC protein (223 kDa). β-
Tubulin (50 kDa) was used to normalize the amount of loaded proteins. (D) 
Immunofluorescence staining on C2C12 cells transposed with hyPB + PB-SPc-DYS-
Pgk-GFP and differentiated in skeletal muscle in vitro upon 4 days in conditioning 
medium (24 days post-EP) showing a co-localized expression of the GFP (in green) and 
the full-length human dystrophin (in red). The condition empty plasmid + PB-SPc-DYS-
Pgk-GFP is shown as negative control. (E) Immunofluorescence staining on the cells 
described in (D) and showing a co-localized expression of the myosin (in white) and the 
full-length human dystrophin (in red) when differentiated in myotubes. Untransfected 
cells are also shown as negative controls. The Ab mouse anti-human dystrophin NCL-
DYS3 was used. The nuclei were stained with Hoechst (Scale bar 100 µm). 
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4.1.4. Isolation and characterization of adult skeletal muscle 
pericyte-derived stem/progenitor cells from the Golden Retriever 
muscular dystrophy (GRMD) dog model 
 Adult pericyte-derived stem/progenitor cells or mesoangioblasts (MABs) were 
isolated from the skeletal muscle of a Golden Retriever Muscular Dystrophy dog, 
as previously described (Sampaolesi et al., 2006; Tonlorenzi et al., 2007). Small, 
round, refractile and poorly adherent cells were visible with the initial outgrowth of 
adherent cells (Figure S1A). This population of cells was collected, kept in culture 
and characterized for the typical markers of adult skeletal muscle MABs 
(Tonlorenzi et al., 2007; Dellavalle et al., 2011). Alkaline phosphatase (AP) 
positive cells were detected in the cultured cell population (Figure S1B). The 
presence of the CD44 marker and the absence of CD34 and CD45 markers were 
assessed by FACS analyses, showing the typical profile of this subset of adult 
pericytes (Figure S1C). Further markers were subsequently analyzed by semi-
quantitative RT-PCR at different time points (passage P5 and P10), using as a 
positive control a heterogeneous bulk cell population directly derived from the 
GRMD muscle biopsy (passage P1). As expected, the transcript levels of PAX7, 
MYF5, CD56 and desmin, typically associated with satellite cells, decreased 
significantly after the first passage (p≤ 0.01, p≤ 0.001; Figures S1D, S1E). In 
contrast, the transcript levels of NG2 and PDGFR β , typical markers of 
pericytes, remained stable over time. Finally, the isolated cell population was 
capable to spontaneously differentiate in vitro into skeletal myotubes or into 
mesodermal lineages upon appropriated stimulation (Figures S1F, S1G). 
Collectively, this gene expression profile and functional analyses confirmed that 
the GRMD cell isolated were bona fide mesoangioblasts. 
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4.1.5. Genetic correction of dystrophic mesoangioblasts by delivery 
of the full-length human dystrophin CDS in PB transposon 
system 
We subsequently optimized the transfection conditions of the dystrophic GRMD 
MABs. These were transfected by electroporation with the hyPB transposase-
encoding construct and the PB-Pgk-GFP transposon (ratio of 0.32 pmol 
transposase DNA: 0.87 pmol transposon DNA) showing a transfection efficiency 
of 44±1% GFP+ cells at 7 days post-EP (Figure 10A). The transfected cells were 
sorted and the GFP expression was maintained, resulting in 88±3% GFP+ cells 
at 28 days post sorting (p≤ 0.001; Figure 10B). In contrast, in the absence of the 
hyPB transposase, the percentage of GFP+ cells gradually declined resulting in 
only background levels of GFP, indistinguishable from untransfected control 
GRMD MABs. This indicates that the sustained GFP expression in the 
transfected MABs could be ascribed to and is dependent on bona fide 
transposition. Based on these encouraging results, we subsequently transfected 
the GRMD MABs by electroporation with the same molar ratios of hyPB 
transposase expression construct and the large-size transposon PB-SPc-DYS-
Pgk-GFP (ratio of 0.32 pmol transposase DNA: 0.87 pmol transposon DNA), 
encoding both full-length human dystrophin and GFP. This resulted in a 
transfection efficiency of 3±1% GFP+ cells at 7 days post-EP (Figure 10A). The 
difference in transfection efficiency between the equimolar doses of PB-SPc-
DYS-Pgk-GFP and PB-Pgk-GFP transposons reflected the different sizes of the 
plasmids, as previously reported (p≤ 0.001, Figure 10A) (Sharma et al., 2013). 
Though doubling the hyPB transposase and transposon doses, while maintaining 
the transposase: transposon ratio, further increased the percentage of GFP+ 
cells (Figure S2), the viability of the transfected cells concomitantly declined (p≤ 
0.001). GRMD MABs transfected with hyPB transposase and PB-SPc-DYS-Pgk-
GFP transposon were sorted at 7 days post-EP, and the GFP expression was 
monitored by FACS analysis and fluorescence microscopy during the 28 days 
post sorting (Figure 10B, 10C). The transfected cells exhibited stable expression 
of 50±5% GFP+ cells, consistent with stable transposition (p≤ 0.001). The 
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transposon copies per diploid genome quantified by qPCR corresponded to 
0.5±0.03 copies for the condition hyPB + PB-SPc-DYS-Pgk-GFP and 1.7±0.04 
copies for hyPB + PB-PgkGFP (Figure 10D). GRMD MABs that were transfected 
with the transposon and without the transposase did not show any detectable 
integrated transposons (p≤ 0.001), indistinguishable from non-transfected control 
cells.  
To assess if the integrated PB-SPc-DYS-Pgk-GFP transposon could result in 
sustained expression of the full-length human dystrophin, transposed GRMD 
MABs were subsequently differentiated in vitro into myocytes/myotubes after 
tamoxifen-induced overexpression of MyoD-ER (Kimura et al., 2008). This 
approach allowed to rescue myogenic differentiation of adult canine MABs at late 
passages (i.e. passage P15-18). The transcript levels of the full-length human 
dystrophin were detected by qRT-PCR (p≤ 0.001; Figure 11A). Moreover, the 
three different regions including the N-terminal, the central region and the C-
terminal region of the full-length human dystrophin transcript were detected by 
RT-PCR in the differentiated GRMD MABs that had undergone transposition 
after transfection with the hyPB transposase and the PB-SPc-DYS-Pgk-GFP 
transposon constructs (Figure 11B). The expression of the full-length human 
dystrophin protein was confirmed by immunofluorescence staining in 
differentiated GRMD MABs, where it co-localized with the expression of GFP 
(Figure 11C) and myosin (Figure 11D) in genetically corrected 
myocytes/myotubes. In contrast, dystrophin and GFP were not detectable in 
untransfected cells nor in the control GRMD MABs co-transfected with the PB-
SPc-DYS-Pgk-GFP transposon and the empty expression plasmid without 
transposase (Figure 11C, 11D). This was consistent with the lack of dystrophin 
mRNA in these controls (Figure 11A, 11B). Similarly, sustained GFP transcript 
levels were detected by qRT-PCR in GRMD MABs that had undergone 
transposition after co-transfection with hyPB transposase and PB-Pgk-GFP 
transposon (p≤ 0.001; Figure 11A). The GFP expression was confirmed by IF in 
differentiated cells (Figure S3). In the absence of the hyPB transposase, GFP 
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transcript and protein were absent, confirming the need for transposition to 
enable stable integration and transgene expression (Figures 10A, S3). 
Taken together, these findings demonstrate that it is possible to genetically 
correct dystrophic adult mesoangioblasts by using a PB-transposon based 
platform to deliver the full-length human dystrophin CDS. 
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Figure 10. PB-mediated transposition of the full-length human dystrophin CDS in 
GRMD MABs. (A) The bar graph shows the percentage of GFP+ GRMD MABs at the 
day of the sorting performed at 7 days post-EP. Optimized and equimolar doses have 
been used in the different conditions. The statistically significant difference in 
transfection efficiency detected when PB-SPc-DYS-Pgk-GFP or PB-Pgk-GFP 
transposon are deployed reflects the different sizes of the plasmids. Results were 
presented as mean±SEM of three independent biological replicates; two-tailed unpaired 
Student’s t-test (***P ≤ 0.001; ns: not significant). (B) The GFP+ populations were 
monitored at different time points for 28 days post sorting. GRMD MABs co-transfected 
with the empty plasmid and the same transposons, and untransfected cells were used 
as controls. Shown are mean±SD on a biological replicate; two-way ANOVA 
(Bonferroni’s multiple comparison test); ***P ≤ 0.001. (C) Live cell imaging showing the 
GFP expression of the different conditions at day 21 post sorting (Scale bar 100 µm). (D) 
Bar graph representing the transposon copies per diploid genome detected by qPCR in 
transposed GRMD MABs (PB-SPc-DYS-Pgk-GFP 0.5 ± 0.03 copies/cell; PB-Pgk-GFP 
1.7 ± 0.04 copies/cell). Shown is mean±SEM, n=3 technical repeats, of one experiment, 
representative of 3 biological repeats; two-tailed unpaired Student’s t-test (*** P ≤ 0.001; 
**P ≤ 0.01).  
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Figure 11. Correction of GRMD MABs by the PB-mediated expression of the full-
length human dystrophin. (A) The transcript levels of the full-length human dystrophin 
(black bars) and GFP (white bars) were detected by qRT-PCR analysis in GRMD MABs 
transposed with hyPB + PB-SPc-DYS-Pgk-GFP or PB-Pgk-GFP. SKM cells have been 
used as positive control. Samples are indicated with (D) when differentiated in 
myocytes/myotubes. Shown is mean±SEM, n=3 technical repeats, of one experiment, 
representative of 3 biological repeats; two-tailed unpaired Student’s t-test (***P ≤ 0.001; 
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**P ≤ 0.01; ns: not significant; D: differentiated sample). (B) RT-PCR demonstrating 
expression of full-length human dystrophin transcript in differentiated 
GRMD MABs that had undergone transposition after co-transfection with hyPB and PB-
SPc-DYS-Pgk-GFP. Three different primer pairs were used that recognize respectively 
(1) the N-terminal, (2) a central region and (3) the C-terminal sequences, yielding 
amplicons of 221 bp, 222 bp and 228 bp, respectively. A schematic representation of the 
PCR primers relative to the different regions of the dystrophin transcript is depicted. 
Controls included differentiated human SKM, untreated differentiated MABs (designated 
as GRMD MABs) and differentiated GRMD MABs co-transfected with the PBSPc-DYS-
Pgk-GFP transposon and an empty expression plasmid without transposase (designated 
as Empty). The primer pairs DYS listed in Table 5 have been used for the positive 
control. L: 50 bp ladder. (C) Immunofluorescence analysis showing the expression and 
the co-localization of the full-length human dystrophin (in red) and the GFP (in green) of 
GRMD MABs corrected with hyPB + PB-SPc-DYS-Pgk-GFP and induced to differentiate 
in skeletal muscle in vitro upon MyoD-ER(T) overexpression after 6 days in conditioning 
medium (21 days post-EP). The condition empty plasmid + PB-SPc-DYS-Pgk-GFP is 
shown as negative control. (D) Immunofluorescence analysis of the cells described in 
(C) showing the expression and co-localization of the full-length human dystrophin (in 
red) and the myosin (in white). Untransfected cells are also shown as negative controls. 
The mouse anti-dystrophin NCL-DYS1 and NCL-DYS2 antibodies were used. The nuclei 
were stained with Hoechst (Scale bar 100 µm). 
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4.2. Genetic correction of DMD HIDEMs by piggyBac 
transposons expressing full-length dystrophin and 
transplantation in dystrophic mice 
 
4.2.1. Generation and characterization of DMD patient-specific 
HIDEMs  
Human iPSC-derived mesoangioblast-like cells (HIDEMs) utilized in this study 
were kindly provided by our collaborator in this study Dr. Tedesco from the 
University College of London (London, United Kingdom). DMD HIDEMs were 
obtained from iPSCs of a patient carrying a deletion of exons 4-43 in the 
dystrophin gene, as described in (Maffioletti et al., 2015; Tedesco et al., 2012; 
Kazuki et al., 2010). HIDEMs from a healthy donor (HD; (Maffioletti et al., 2015; 
Tedesco et al., 2012)) were used as control, where indicated.  
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Briefly, DMD iPSCs were disaggregated to a single cell suspension and induced 
to differentiate into expandable cells resembling human MABs using a procedure, 
which entails four stages with different culture densities, media and surface 
coating. This was achieved without requiring the generation of embryoid bodies 
or prospective cell isolation. Human iPSC differentiation with this protocol 
yielded relatively homogeneous MAB-like cells populations. Cell 
characterization by flow cytometry was performed to ensure that the desired cell 
population was obtained. Specifically, the markers assessed were the following: 
CD13, CD31, CD44, CD45, CD49b, CD56, CD146, alkaline phosphatase (AP) 
and stage-specific embryonic marker 4 (SSEA4). In brief, CD146 (a perivascular 
marker in vivo), CD13, CD44 and CD49b expression were highly expressed in 
normal or DMD patient-specific HIDEMs (above 50%). CD56 (myoblast marker), 
CD45 (pan-hematopoietic marker) and CD31 (endothelial cell marker) were very 
low or negative. SSEA4, a pluripotency-associated marker, was either negative 
or lowly expressed. Expression of the quintessential pluripotency marker OCT4, 
NANOG, SOX2 and KLF4 in HIDEMs was either very low or absent. 
 
The DMD HIDEMs (or normal healthy donor HIDEMs as control) were 
subsequently induced to differentiate into multinucleated skeletal myotubes 
following transduction with a tamoxifen-inducible MyoD lentiviral (MyoD-ER(T) 
LV) vector that triggers and synchronizes the differentiation of the entire culture. 
Following induction with tamoxifen, the HIDEM-derived myotubes expressed de 
novo the terminal myogenic differentiation marker myosin heavy chain (MyHC) 
as shown by immunofluorescence staining. We have also incidentally observed 
the formation of sarcomeric striations and spontaneous twitching of myotubes 
derived from HIDEMs after 8 days in myogenic differentiation medium 
(Supplementary video 1 in Maffioletti et al., 2015).  
 
We have shown that PB transposons could efficiently transfer the full-length 
dystrophin coding DNA sequence (CDS, size: 11.1 kb) and correct dystrophic 
MABs when co-transfected with the hyperactive PB (hyPB) transposase (see 
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above – Chapter 4.1; (Loperfido et al., 2015b)). In contrast to MABs that have a 
limited proliferation potential, DMD HIDEMs has a greater expansion potential 
and constitute a suitable alternative target for genetic modification with this PB 
transposon system, given their ability to undergo relatively robust and 
synchronous myogenic differentiation.    
 
4.2.2. Stable GFP expression after PB transposition in DMD HIDEM 
and DMD HIDEMMYOD cells 
To engineer the DMD HIDEMs with the PB transposons, we explored two 
alternative protocols. For the first approach, DMD HIDEMs were first transfected 
with the PB transposon components and subsequently transduced with the 
tamoxifen-regulated MyoD-ER(T) LV vectors, followed by the tamoxifen-
mediated induction of myogenic differentiation (Figure 12A). Alternatively, DMD 
HIDEMs were first transduced with the MyoD-ER(T) LV vectors (designated as 
DMD HIDEMMYOD cells) and subsequently transfected with the PB transposon 
components, followed by the tamoxifen-mediated induction of myogenic 
differentiation (Figure 12B).  
 
DMD HIDEMs were first co-transfected with the hyPB transposase and a small 
size transposon coding for GFP (designated as PB-Pgk-GFP; transposon size: 
5.4 kb). Two different concentrations were used in order to determine the optimal 
conditions of transfection (0.32 pmol transposase DNA: 0.87 pmol transposon 
DNA and 0.64 pmol transposase DNA: 1.74 pmol transposon DNA) based on our 
previous results obtained in bona fide MABs transfected with the PB transposon 
(see above – Chapter 4.1; (Loperfido et al., 2015b)). At 8 days post-
electroporation (post-EP), 9% of GFP+ cells were detected when the lowest 
transposase: transposon concentration was used, whereas the percentage of 
GFP+ cells increased to 20% at the highest transposase: transposon 
concentration. The transfected cells were enriched for GFP expression by 
fluorescence-activated cell sorting and showed a stable GFP expression for at 
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least 45 days post-EP (i.e. 38 days post-sorting) in 97% and 99% of the 
transfected DMD HIDEMs. (Figure 13A). 
Similar results were obtained when we transfected DMD HIDEMs that were 
already transduced with the MyoD-ER(T) LV vectors prior to transfection with the 
transposon and transposase constructs, named DMD HIDEMMYOD cells. 
Sustained GFP expression could be achieved upon transfection of the PB-Pgk-
GFP transposon with the hyPB expression construct in DMD HIDEMMYOD cells. In 
particular, stable GFP expression could be detected for at least 45 days post-EP 
in 93% and 95% of the sorted DMD HIDEMMYOD cells respectively when low and 
high concentrations were used (Figure 13A). When the DMD HIDEM or DMD 
HIDEMMYOD cells were transfected with the PB-Pgk-GFP transposon and an 
empty expression construct that did not encode for any transposase, sustained 
GFP expression was not detectable. 
Both protocols enabled efficient myogenic differentiation of the DMD HIDEM or 
DMD HIDEMMYOD cells upon co-transfection with the hyPB transposase and the 
small size transposon coding for GFP and followed by the tamoxifen-mediated 
induction, consistent with the co-localized expression of MyHC and the transgene 
GFP encoded by the PB transposons (Figure 13B).  
 
Subsequently, we co-transfected DMD HIDEMs with the hyPB transposase and a 
large PB transposon encoding a full-length human dystrophin coding DNA 
sequence (CDS, size: 11.1 kb) and a GFP reporter gene  (designated as PB-
SPc-DYS-Pgk-GFP; transposon size: 17 kb) (see above – Chapter 4.1; 
(Loperfido et al., 2015b)).  The same molar ratios were employed, as in the 
previous experiment (i.e. 0.32 pmol transposase DNA: 0.87 pmol transposon 
DNA and 0.64 pmol transposase DNA: 1.74 pmol transposon DNA). At 8 days 
post-EP, the percentage of GFP+ cells in the unsorted samples was respectively 
1.5% and 2.5% upon usage of low and high DNA plasmid concentrations. The 
transfected cells were enriched for GFP expression by fluorescence-activated 
cell sorting and the GFP expression was monitored at different time-points post-
EP by live imaging using fluorescence microscopy (Figure 14). At 45 days post-
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EP (i.e. 38 days post-sorting), the percentage of the GFP+ cells was 86% and 
90% of the DMD HIDEMs transfected with low and high plasmid concentrations, 
respectively. 
Similarly, we co-transfected the DMD HIDEMMYOD cells with the large size PB-
SPc-DYS-Pgk-GFP transposon along with the hyPB transposase. This resulted 
in 79% and 77% of GFP+ DMD HIDEMMYOD cells at 45 days post-EP (Figure 14). 
As negative controls, untransfected cells and DMD HIDEMs co-transfected with 
an empty expression plasmid devoid of transposase and the PB-SPc-DYS-Pgk-
GFP transposon did not show any stable GFP expression (Figure 14). 
Collectively, these results indicate that transposition mediated by the hyPB 
transposase is a prerequisite to enable stable GFP expression in the transfected 
DMD HIDEM or DMD HIDEMMYOD cells. The highest concentration of PB 
transposon components gave the highest percentage in GFP+ of DMD HIDEM or 
DMD HIDEMMYOD cells. These could be easily enriched for the reporter marker 
via cell sorting.  We therefore continued our investigation on the cells transposed 
with the highest concentration of PB transposons. 
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Figure 12. Schematic representation of the two protocols used in this study to 
obtain stable transposition in HIDEMs. (A) A first approach used in this study for 
genetic correction of DMD HIDEMs. DMD HIDEMs with deletion of exons 4–43 in the 
dystrophin gene were electroporated with hyPB transposase and PB-Pgk-GFP or PB-
SPc-DYS-Pgk-GFP transposons. Subsequently, they were enriched for the GFP 
expression by fluorescence-activated cell sorting. In vitro myogenic differentiation was 
induced upon transduction with lentiviral vectors coding for the tamoxifen-inducible 
MyoD-ER(T) (MyoD-ER(T) LV vectors), followed by tamoxifen exposure. The expression 
of the GFP and/or the full-length human dystrophin was investigated in genetically 
corrected DMD HIDEMs upon myogenic differentiation in vitro. (B) A second approach to 
genetically correct DMD HIDEMs previously transduced with MyoD-ER(T) LV vectors 
and named DMD HIDEMMYOD cells. These were electroporated with hyPB transposase 
and PB-Pgk-GFP or PB-SPc-DYS-Pgk-GFP transposons. Transfected cells were 
enriched for the GFP expression by fluorescence-activated cell sorting and exposed to 
tamoxifen in order to induce the myogenic differentiation. The expression of the GFP 
and/or the full-length human dystrophin was investigated in genetically corrected DMD 
HIDEMMYOD cells upon myogenic differentiation in vitro. 
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Figure 13. Stable GFP expression after transposition of the small size transposon 
PB-Pgk-GFP. (A) Live cell imaging of DMD HIDEM and DMD HIDEMMYOD cells 
transfected with hyPB and the small size transposon PB-Pgk-GFP. Pictures acquired at 
45 days post-EP by fluorescence microscopy show the stable expression of the GFP 
reporter in DMD HIDEM and DMD HIDEMMYOD cells at the concentration of 0.32 pmol 
transposase DNA: 0.87 pmol transposon DNA and 0.64 pmol transposase DNA: 1.74 
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pmol transposon DNA. As negative controls, cells transfected with the empty plasmid 
and PB-Pgk-GFP transposons are also shown. Above the pictures, the percentage of 
GFP+ cells acquired by the fluorescence-activated cell sorter is reported. Scale bar 75 
µm. (B) Immunofluorescence assay of DMD HIDEM and DMD HIDEMMYOD cells 
transfected with hyPB + PB-Pgk-GFP at the high concentration of 0.64 pmol 
transposase DNA: 1.74 pmol transposon DNA, and differentiated upon over-expression 
of tamoxifen-inducible Myo-ER(T). Differentiated cells are positive for GFP (in green) 
and MyHC (in red) in both the protocols used. Scale bar 100 µm.   
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Figure 14. Stable GFP expression after transposition of the large size transposon 
PB-SPc-DYS-Pgk-GFP. Live cell imaging of DMD HIDEM and DMD HIDEMMYOD cells 
transfected with hyPB and the large size transposon PB-SPc-DYS-Pgk-GFP. Pictures 
acquired at 45 days post-EP by fluorescence microscopy show the stable expression of 
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the GFP reporter in DMD HIDEM and DMD HIDEMMYOD cells at the concentration of 0.32 
pmol transposase DNA: 0.87 pmol transposon DNA and 0.64 pmol transposase DNA: 
1.74 pmol transposon DNA. As negative controls, cells transfected with the empty 
plasmid and PB-Pgk-GFP transposons and untransfected cells are also shown. Above 
the pictures, the percentage of GFP+ cells acquired by the fluorescence-activated cell 
sorter is reported. Scale bar 75 µm. 
 
4.2.3. Correction of DMD HIDEM or DMD HIDEMMYOD cells mediated 
by PB transposons coding for full-length human dystrophin CDS 
As described above, according to one protocol DMD HIDEMs transfected with 
the PB transposons were subsequently transduced with the tamoxifen-regulated 
MyoD-ER (T) LV vectors followed by the tamoxifen-mediated induction of 
myogenic differentiation (Figure 12). Alternatively, the DMD HIDEMMYO cells, that 
were first transduced with the MyoD-ER(T) LV vector and subsequently 
transfected with the PB transposons, were also subjected to  tamoxifen to  
induce myogenic differentiation. 
Transcription levels of the full-length human dystrophin were detected by 
quantitative reverse transcriptase PCR (qRT-PCR) in DMD HIDEMs transfected 
with hyPB and PB-SPc-DYS-Pgk-GFP, either in a proliferative state or in 
terminally differentiated myotubes (Figure 15A). Similarly, the expression of the 
GFP mRNA was confirmed by qRT-PCR in DMD HIDEMs transfected with hyPB 
and PB-SPc-DYS-Pgk-GFP or the small size transposon PB-Pgk-GFP. In 
contrast, dystrophin and GFP transcripts were not detected in cells derived from 
the control DMD HIDEMs that were either non-transfected or transfected with the 
transposons without hyPB transposase (Figure 15A). This again provided 
independent confirmation that hyPB transposase-mediated transposition was 
required for stable GFP and dystrophin gene expression.  
To ascertain the full-length size of the human dystrophin transcript encoded by 
the PB transposons, an RT-PCR was performed to amplify three different regions 
corresponding to the N-terminal, the central and the C-terminal sequences of the 
full-length dystrophin transcript, as described in (Loperfido et al., 2015b). The 
three corresponding PCR bands were detected in the differentiated DMD HIDEM 
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or DMD HIDEMMYOD cells where the transposon PB-SPc-DYS-Pgk-GFP 
integrated upon co-transfection with hyPB transposase confirming the presence 
of the full-length dystrophin transcript (Figure 15B, S4). In contrast, these bands 
were absent in untreated cells or when an empty transposase plasmid was used.  
Consistent with the expression results at the transcriptional level, expression of 
the full-length human dystrophin protein (427 kDa) was detected by Western blot 
analysis in differentiated DMD HIDEM cells genetically corrected with the hyPB 
transposase and PB-SPc-DYS-Pgk-GFP transposon, upon myogenic 
differentiation in vitro (Figure 15C). In contrast, the dystrophin protein could not 
be detected in differentiated cells derived from untransfected DMD HIDEMs or in 
differentiated DMD HIDEMs that were co-transfected with PB-SPc-DYS-Pgk-
GFP and an empty expression plasmid without transposase. Normal skeletal 
muscle cells differentiated into myotubes in vitro were used as positive control. 
These data were confirmed by using the immunofluorescence assay where the 
expression of the full-length human dystrophin protein co-localized with the 
expression of GFP and myosin in multinucleated myotubes of genetically 
corrected DMD HIDEMs (Figure 15D). Similarly, GFP protein expression was 
detected in differentiated DMD HIDEMs transfected with the hyPB transposase 
and small size PB-Pgk-GFP transposon (Figure 13B). Dystrophin and GFP were 
not detectable in the control cells (i.e. in the absence of transposase in 
transfected cells or in untransfected cells), indicating that transposition is 
required for the stable and prolonged gene expression into the target cells. 
 
Collectively, these results demonstrate that it is possible to genetically correct 
DMD patient-specific iPSC-derived myogenic cells using a PB transposon 
system encoding the full-length human dystrophin.  
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Figure 15. PB-mediated genetic correction of DMD HIDEMs. (A) Bar graph depicting 
the transcription levels of the full-length human dystrophin (black bars) and GFP (white 
bars) detected by qRT-PCR analysis in DMD HIDEMs transfected with hyPB and PB-
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SPc-DYS-Pgk-GFP or PB-Pgk-GFP, when in proliferation or in differentiated myotubes 
(D: differentiated sample; UNTR: untransfected DMD HIDEMs; SKM: skeletal muscle 
cells). The transcription levels were not detected in untransfected cells or when the 
empty plasmid devoid of any transposase was used. Data were normalized to the 
GAPDH housekeeping gene. Shown is mean±SEM, n=3 technical repeats, of one 
experiment, representative of 3 biological repeats; two-tailed unpaired Student’s t-test 
(***P ≤ 0.001; **P ≤ 0.01). (B) RT-PCR showing expression of full-length human 
dystrophin transcript in differentiated DMD HIDEMs that had undergone transposition 
after co-transfection with hyPB and PB-SPc-DYS-Pgk-GFP. Three different primer pairs 
were used that recognize respectively (1) the N-terminal, (2) a central region and (3) the 
C-terminal sequences, yielding amplicons of 221 bp, 222 bp and 228 bp, respectively. A 
schematic representation of the PCR primers relative to the different regions of the 
dystrophin transcript is depicted above the picture. Negative controls included 
differentiated untreated DMD HIDEMs and differentiated DMD HIDEMs co-transfected 
with the PB-SPc-DYS-Pgk-GFP transposon and an empty expression plasmid without 
transposase (designated as Empty). Normal skeletal muscle (SKM) cells differentiated in 
myotubes were used as a positive control; the primer pairs DYS listed in Table 5 have 
been used for this sample. L: 50 bp ladder. (C) Western blot analysis showing the 
expression of the full-length human dystrophin protein (427 kDa) in DMD HIDEMs 
genetically corrected with hyPB + PB-SPc-DYS-Pgk-GFP and upon myogenic 
differentiation in vitro. The full-length human dystrophin protein was confirmed in normal 
skeletal muscle (SKM) cells differentiated in myotubes in vitro. As negative controls, 
differentiated untransfected DMD HIDEMs or co-transfected with the PB-SPc-DYS-Pgk-
GFP transposon and an empty expression plasmid without transposase (designated as 
Empty) were included. β-Tubulin (50 kDa) was used to normalize the amount of loaded 
proteins (MW: molecular weight). (D) Immunofluorescence assay depicting the co-
localized expression of GFP (in green), full-length dystrophin (in red) and myosin (in 
white) in DMD HIDEMs genetically corrected with hyPB + PB-SPc-DYS-Pgk-GFP and 
differentiated in multinucleated myotubes upon over-expression of tamoxifen-inducible 
MyoD-ER(T). Expression of GFP and dystrophin was absent in differentiated DMD 
HIDEMs co-transfected with the empty plasmid and in differentiated untransfected DMD 
HIDEMs. Scale bar 75 µm. 
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4.2.4. Transplantation of genetically corrected DMD HIDEMMYOD cells 
in scid/mdx mice and safety 
Transplantation of genetically corrected DMD HIDEMMYOD cells was performed 
intramuscularly in scid/mdx mice as previously described (Gerli et al., 2014). This 
animal model of DMD lacks functional B and T lymphocytes, thus allowing the 
evaluation of engraftment and regenerative potential of DMD genetically 
corrected cells in dystrophic mice avoiding a possible immune rejection against 
xenogeneic and manipulated cells. Scid/mdx mice were pretreated with intra-
peritoneal injections of tamoxifen during the three days prior to- and post-
transplantation, once a day. This would allow the transplanted cells, previously 
transduced with the tamoxifen-inducible MyoD(ER) cassette, to be exposed to 
levels of tamoxifen necessary to activate and synchronize their myogenic 
differentiation in vivo (Gerli et al., 2014; Tedesco et al., 2012). The genetically 
corrected DMD HIDEMMYOD cells were as well pretreated with tamoxifen for 24 
hours and injected in the tibialis anterior (or gastrocnemius) muscles of the 
scid/mdx mice. As positive controls, HIDEMs generated from healthy donors 
transduced with MyoD-ER(T) LV vectors were also transplanted. Muscles 
injected with PBS were used as negative controls.  
Transplanted and control muscles were harvested at 1 week and 3 weeks after 
the injection and processed. Cell engraftment and differentiation were then 
assessed by immunofluorescence assay on the transplanted muscles. An 
antibody against Lamin A/C was used to detect grafted human cell nuclei, while a 
combination of two antibodies against respectively the central domain and C-
terminal region of the dystrophin were used to detect donor-derived restoration of 
the protein absent in the dystrophic mice. An antibody against laminin was 
employed to visualize the overall structure of the muscle. The genetically 
corrected DMD HIDEMMYOD cells engrafted in the host muscles and were able to 
express the full-length human dystrophin mediated by the PB transposon into the 
recipient skeletal muscle fibers, one week after the transplantation (Figure 16A, 
16B). Accordingly, the healthy donor HIDEMs were also detected in the injected 
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muscles and were able to express the human dystrophin, correctly localized on 
the myofiber membrane (Figure 16A). 
 
In order to assess the safety of the manipulated cells for in vivo applications, a 
tumor formation assay was performed. DMD HIDEMs co-transfected with hyPB 
transposase and PB-SPc-DYS-Pgk-GFP transposon (n= 8) or PB-Pgk-GFP 
transposon (n= 8) and transduced with MyoD-ER(T) LV vectors were injected 
subcutaneously in immunodeficient nude mice. As controls, untransfected DMD 
HIDEMs with and without MyoD-ER(T) LV vector transduction  (n= 4 and n= 2, 
respectively) were utilized. HeLa cells, a tumorigenic cell line, were injected as a 
positive control (n= 2). After 4 months, no tumors developed in nude mice 
transplanted with the different HIDEM cell lines (n= 22). In contrast, tumor 
formation was observed in the nude mice transplanted with HeLa cells after 1 
month (Figure 17). This is consistent with previous reports demonstrating the 
non-tumorigenic nature of the HIDEMs (Tedesco et al., 2012) and the safety of 
PB transposons as delivery tools for gene therapy (Di Matteo et al., 2014b).  
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Figure 16. PB-mediated full-length dystrophin expression in scid/mdx mice upon 
transplantation of genetically corrected DMD HIDEMMYOD cells. (A) 
Immunofluorescence staining of a section of tibilias anterior muscle of scid/mdx mice 
(upper panel) after intramuscular injection of 1x 106 DMD HIDEMMYOD cells genetically 
corrected with hyPB and PB-SPc-DYS-Pgk-GFP. The muscle showed the engraftment 
of the cells as revealed by a cluster of myofibers positive for the dystrophin (in red) 
containing donor human cell nuclei positive for lamin A/C (in green) a week after the 
intramuscular transplantation. Revertant fibers from scid/mdx mice can also be identified 
by the expression of the dystrophin and the absence of lamin A/C positive nuclei. 
Laminin (in grey) was used to visualize the overall structure of the muscle. The nuclei 
were stained with Hoechst. As positive control, healthy donor HIDEMs engrafted in a 
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gastrocnemius muscle of scid/mdx mice were also showed (lower panel). Scale bar 75 
µm. (B) Higher magnification of the immunofluorescence staining in (A). 
 
 
Figure 17. Tumor formation assay. (A) Pictures of nude mice transplanted 
subcutaneusly respectively with DMD HIDEMMYOD cells genetically corrected with hyPB 
+ PB-SPc-DYS-Pgk-GFP (left mouse) and HeLa cells (right mouse). They were 
sacrificed respectively at 4 months and 1 month after the injection. Only nude mice 
injected with HeLa cells developed tumors. (B) Picture of a tumor developed from HeLa 
cells and harvested at necropsy. (C) Immunofluorescence staining for lamin A/C 
confirmed the human origin of the tumor from HeLa cells. Scale bar 75 µm. 
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Chapter 5 
 
5. General conclusion  
In this study, we have demonstrated that the hyperactive piggyBac (PB) 
transposon technology could be used to obtain stable expression of a 
therapeutically relevant, large-sized transgene such as the full-length human 
dystrophin coding DNA sequence (CDS). Myogenic stem/progenitor cells derived 
from a dystrophic large animal model for Duchenne muscular dystrophy (DMD) 
or generated from DMD patient-specific induced pluripotent stem cells (iPSCs) 
could be genetically corrected upon stable integration of the PB transposons into 
their genome. The expression of the full-length human dystrophin was 
successfully detected upon myogenic differentiation in vitro and transplantation in 
immunodeficient dystrophic mice in vivo. To our knowledge, this is the first report 
that ascertains the use of PB transposons coding for the full-length human 
dystrophin enabling genetic correction of dystrophic mesoangioblasts or DMD 
patient-specific iPSC-derived myogenic cells. It is particularly encouraging that 
genetically corrected DMD HIDEMs were able to express the therapeutic protein 
upon transplantation in vivo in immunodeficient dystrophic mice, without 
discernable adverse events. This establishes proof-of-concept and may 
ultimately pave the way towards a new non-viral gene therapy approach to treat 
DMD patients. This approach offers the possibility to express a functional copy of 
full-length dystrophin while regenerating new skeletal muscle. At variance with 
other methods, this approach could potentially be applied to all the different 
mutations observed in DMD patients and extended to other forms of muscular 
dystrophies. Further pre-clinical in vivo studies in large animal models are 
needed to ultimately justify a possible use of PB transposons expressing full-
length human dystrophin in clinical trials for DMD.  
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Chapter 6 
 
6. Discussion  
Recent studies aimed to explore the use of transposons to investigate 
therapeutic strategies in muscular dystrophies, but these were limited to the use 
of reporter or marker genes (Ley et al., 2014; Muses et al., 2011a; Quattrocelli et 
al., 2011; Belay et al., 2010), truncated versions of either dystrophin or utrophin 
(Filareto et al., 2015, 2013; Muses et al., 2011b) or conditionally immortalized 
muscle cell-derived cell-lines (Muses et al., 2011a, 2011b) that cannot be 
clinically deployed.  To our knowledge, this is the first report that establishes the 
use of transposons coding for the full-length human dystrophin enabling genetic 
correction of dystrophic primary cells or derived from dystrophic iPSCs.  
 
The main advantage of PB transposons is that they efficiently integrate their 
cargo into the target cell genome. This property enables robust stable gene 
expression in both human and mouse cells, ex vivo or in vivo (reviewed in (Di 
Matteo et al., 2012; VandenDriessche et al., 2009); (Di Matteo et al., 2014a; 
Matsui et al., 2014; Doherty et al., 2012; Yusa et al., 2011; Nakazawa et al., 
2009; Ding et al., 2005)). This attribute is particularly relevant for stable genetic 
modification of stem/progenitor cells and pluripotent stem cells given their 
intrinsic self-renewal and differentiation potential (Belay et al., 2011). As we 
observed in this study, PB transposons can integrate and yield sustained 
dystrophin expression in dystrophic MABs isolated from the Golden Retriever 
muscular dystrophy dog and mesoangioblast-like cells derived from DMD patient-
specific iPSCs (HIDEMs) upon their myogenic differentiation.  
In contrast, in the absence of any transposase-expressing construct, transgene 
expression lasted only for short term. This indicates that bona fide transposition 
was a prerequisite for robust dystrophin expression in dystrophic MABs and 
HIDEMs. It is known that transfection of conventional plasmids results in a very 
low stable integration frequency  (typically 1 stable integrant per 105 transfected 
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cells) (Izsvák et al., 2009; VandenDriessche et al., 2009), consequently 
hampering its potential clinical applications.  
The efficiency of PB transposon-mediated delivery of the full-length human 
dystrophin CDS compares favorably with alternative approaches that allowed the 
production of the wild-type full-length dystrophin protein, such as the human 
artificial chromosome (HAC; (Tedesco, 2015; Kouprina et al., 2014)). This vector 
is recognized as an endogenous chromosome within the host cells and is stably 
maintained throughout subsequent cell divisions obviating the need for genomic 
integration. The entire human dystrophin genomic locus (2.4 Mb), including the 
native promoter and regulatory elements, has been accommodated into the HAC 
(Hoshiya et al., 2009) and transferred in dystrophic mesoangioblasts isolated 
from mdx mice and in DMD patient-specific iPSCs (Tedesco et al., 2011; Kazuki 
et al., 2010). This approach resulted in full-length human dystrophin expression 
in the genetically corrected cells. However, the generation of such a relatively 
complex vector like HAC, together with the low efficiency of microcell-mediated 
chromosome transfer  (MMCT; approximately 1.2x 10-5) required to introduce 
HACs into the target cells, may limit the application of this technology only to 
clonogenic stem/progenitor cells with high proliferation potential. On the other 
hand, the use of PB transposons is at least 104-fold more efficient than MMCT 
and may ease the manufacturing constrains compared to MMCT or viral vectors, 
ultimately facilitating ultimate clinical translation of the PB transposon vectors.  
 
Another advantage of the PB transposons is that they enabled stable delivery of 
the full-length human dystrophin CDS together with a reporter marker (insert 
size: 13.7 kb). This exceeds the packaging capacity of γ-retroviral and lentiviral 
vectors (< 10 kb) and AAV vectors (~5 kb). Consequently, this obviates concerns 
associated with the use of truncated dystrophins that may not replicate all of the 
necessary functions of its wild-type counterpart (Sampaolesi et al., 2006). 
Moreover, expression of full-length human dystrophin is broadly applicable to all 
patients suffering from DMD, regardless of the underlying genetic defect in the 
dystrophin locus. This is in contrast with other approaches that are restricted in 
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their application to correcting specific mutations of the gene, such as exon-
skipping strategies or the use of engineered nucleases, although advances in 
these fields to target multiple mutations are under investigation (Ousterout et al., 
2015b; Echigoya and Yokota, 2014). The ability of PB transposons to deliver 
such a relatively large cargo is consistent with previous reports indicating that PB 
transposons can mediate the transfer of large genetic cargos up to 100 kb (Li et 
al., 2011; Ding et al., 2005). The availability of PB transposons encoding either 
full-length or truncated dystrophin CDS characterized in this study may pave the 
way towards future comprehensive structure-function and comparative studies. 
Indeed, the present study has broader implications for the use of other 
hyperactive transposon systems, such as Sleeping Beauty for gene therapy of 
DMD (Muses et al., 2011b; Grabundzija et al., 2010; Huang et al., 2010). 
 
In the present study, we have used nucleofection technology, an electroporation-
based transfection method that allows to transfer the DNA plasmids directly into 
the nuclei and the cytoplasm of both dividing and non-dividing the cells in vitro 
(Izsvák et al., 2009; Hollis et al., 2006). This technique overcomes the limitations 
related to other transfection methods that rely on nuclear import of plasmid DNA 
in non-dividing cells (Al-Dosari and Gao, 2009; Midoux et al., 2009). The 
transfection efficiency of hyPB transposase and the large size PB transposon in 
DMD HIDEMs was within the range of what could be obtained in dystrophic 
MABs. Nevertheless, large-size DNA plasmids adversely impact on the 
transfection efficiency (Sharma et al., 2013). In accordance with these previous 
findings, we showed that the use of large transgenes (i.e. full-length human 
dystrophin CDS) as opposed to smaller transgenes (i.e. truncated MD1 and MD2 
human microdystrophin CDS, GFP transgene) adversely impacts on the 
transfection efficiency in MABs and HIDEMs. This may be due, at least in part, to 
the intrinsic property of the DNA plasmids such as the presence of unmethylated 
CpG motifs in the backbone sequences that might impair cell viability, possibly 
involving Toll-like receptor (TLR) pathways (Reyes-Sandoval and Ertl, 2004; 
Krieg et al., 1995). Indeed, plasmids with a low content in CpG motifs confer 
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long-term gene expression with less toxicity (Hyde et al., 2008; Yew et al., 2001). 
Alternatively, transfection efficiency may also have been affected by impaired 
nuclear import of plasmid DNA due to reduced cytosolic mobility of large size 
plasmid DNA (Lukacs et al., 2000).  
 
We demonstrated that the use of the hyperactive PB transposase (Yusa et al., 
2011) compared to the non-hyperactive mPB transposase (Cadiñanos and 
Bradley, 2007) can boost the efficiency and stable expression of large-size 
transposons. After nucleofection, the surviving transfected cells could be easily 
enriched by FACS sorting yielding more than 50% GRMD MABs and 80 to 90% 
DMD HIDEMs that had undergone stable transposition, as confirmed from the 
presence of PB transposon copies integrated in the genome of in these cells. 
Nevertheless, it may be worthwhile to further explore alternative strategies to 
augment the overall transfection efficiency, viability and expression of the 
therapeutic gene. This could potentially be achieved by using a minicircle-based 
transposon system, devoid of any bacterial backbone sequence, as recently 
validated for Sleeping Beauty (Sharma et al., 2013). Consequently, this would 
reduce the plasmid size, lower CpG content, increase transfection efficiency and 
decrease DNA toxicity. Alternatively, more potent muscle-specific promoters in 
combination with enhancers could be used to drive expression of the full-length 
dystrophin CDS (Jonuschies et al., 2014; Rincon et al., 2014; De Bleser et al., 
2007). 
 
The therapeutic relevance of MABs, even after prolonged in vitro culture, has 
been highlighted in many previous studies (Domi et al., 2015; Tedesco et al., 
2011; Díaz-Manera et al., 2010; Sampaolesi et al., 2006; Palumbo et al., 2004; 
Sampaolesi et al., 2003). Their intrinsic capability to cross the wall vessels when 
injected intra-arterially and to contribute to the muscle regeneration in animal 
models has represented a substantial advantage over other muscle stem cells 
(i.e. myoblasts) (Dellavalle et al., 2007). We have confirmed the characteristic 
phenotype of the MABs used in our study based on the expression of adult dog 
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MAB markers and their ability to undergo myogenic differentiation in vitro. As 
reported in the literature (Sampaolesi et al., 2006), adult dog MABs have a 
myogenic potential that is activated upon fusion with myoblasts or after exposure 
to MyoD. Accordingly, in our study genetically corrected GRMD mesoangioblasts 
were transduced to express the tamoxifen-inducible MyoDER(T) and undergo 
myogenic differentiation at late passage in vitro (i.e. passage P15-18). 
 
According to previous and recent studies on human MABs, a high proliferation 
rate has been observed for approximately 20 population doublings, with a 
doubling time of approximately 36 h (Cossu et al., 2015; Dellavalle et al., 2007) 
without compromising their stem cell properties. Though the initial transfection 
efficiency in GRMD MABs was about 3%, we could rapidly enrich for those cells 
that had undergone stable transposition by FACS sorting, thus avoiding 
protracted cell culture.  
Dystrophin levels corresponding to 30% of the levels normally found in healthy 
individuals and in animal models are sufficient to prevent muscular dystrophy 
(Neri et al., 2007; Wells et al., 1995). In accordance with these data, pre-clinical 
studies based on the use of MABs have shown a therapeutic effect in dystrophic 
mice and dogs with dystrophin expression ranging 5 to 30% of normal levels 
(Tedesco et al., 2011; Sampaolesi et al., 2006). This has been achieved by 
injecting 1x106 cells/muscle in the mouse and 5x107 cells/kg in the dog model. 
Considering treatment of pediatric subjects with less advanced muscle disease 
and more likely to benefit from this cell therapy, this would translate into a total 
cell dose of 75x107 MABs in a 15 kg patient although the possibility of repeated 
injection to reach efficacy still needs to be investigated. Up to 2x109 human 
MABs can readily be obtained after in vitro expansion of initial cells isolated from 
a single muscle biopsy (100–200 mg) (Cossu et al., 2015; Dellavalle et al., 2007). 
Based on our current results, we estimated that 9x108 stably transfected GRMD 
MABs expressing dystrophin after PB-mediated transposition could be obtained 
35 days post-transfection of 3x106 cells. Consequently, the required dose to treat 
pediatric DMD patients is within reach. It is encouraging that initially more MABs 
 136 
outgrew from explants of young DMD patients (Dellavalle et al., 2007) suggesting 
that the yield of MABs and/or their proliferative capacity may possibly be even 
higher in younger than in older patients with advanced disease.  
 
Allogeneic MABs have recently been tested in a first-in-human phase I/II clinical 
trial in DMD patients under immunosuppressive treatment (EudraCT N° 2011-
000176-33, (Cossu et al., 2015)). Administration at escalating doses of HLA-
matched donor MABs in the limb arteries of the patients was considered 
relatively safe, which was the primary endpoint of the study. One patient 
developed an acute thalamic stroke with no clinical consequences but it was 
unclear whether it correlated with the MAB infusion. Muscle biopsies confirmed 
the presence of donor DNA in 4/5 patients and expression of donor dystrophin in 
one patient. Though no functional improvements were observed in the treated 
patients, functional measures stabilized in 2/3 ambulant patients. The study also 
provided insights to further improve efficacy by enrolling younger patients with 
less advanced muscle disease and/or increase the MAB dose. Moreover, the use 
of gene-modified autologous MABs may further augment the efficacy with the 
added advantage over allogeneic MABs that immune suppression may not be 
needed in this case. 
 
Though MABs can be expanded extensively for 20 passages and exhibit a 
remarkable proliferative potential, their lifespan is nonetheless limited (Tonlorenzi 
et al., 2007). This likely reflected normal cellular processes that gradually 
contribute to cellular senescence (Holliday, 2014). In addition, the PB transposon 
technology is potentially amenable to be used in alternative adult myogenic stem 
cell sources distinct from MABs (Costamagna et al., 2015; Benedetti et al., 
2013). Ultimately, the use of iPSC-derived myogenic cells, that have unlimited 
expansion potential, may represent an attractive alternative, provided they can 
safely and efficiently be converted into transplantable myogenic cells (reviewed 
in (Loperfido et al., 2015a). Therefore, in the present study we have validated the 
use of PB transposon system coding for the full-length dystrophin to genetically 
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corrected HIDEMs, generated from a DMD patient (Tedesco et al., 2012). As 
previously described in our studies, a stepwise protocol for differentiating 
pluripotent stem cells towards the mesodermal lineage allowed the generation of 
the DMD HIDEMs (Maffioletti et al., 2015). These cells resemble 
mesoangioblasts for morphology, surface markers and gene expression profile. 
Nevertheless, HIDEMs show unlimited proliferation capacity in contrast to most 
primary myogenic cells. Upon tamoxifen-inducible MyoD overexpression, the 
myogenic differentiation of HIDEMs could be accomplished in vitro or after 
transplantation into immune-deficient dystrophic mice in vivo (Maffioletti et al., 
2015; Gerli et al., 2014; Tedesco et al., 2012). Although a synchronized 
activation and differentiation has been observed in the whole culture in vitro, the 
analysis of the temporal control of the tamoxifen on the myogenic activation of 
the HIDEMs (or MIDEMs) in vivo needs further investigation. The use of muscle-
specific promoters and enhancer elements could be employed to circumscribe 
the activation of the tamoxifen-driven myogenic differentiation to the muscle 
compartment and improve the strategy. Nevertheless, other methods can also be 
used to provide MyoD for myogenic differentiation, as reviewed in (Loperfido et 
al., 2015a).  
 
In the current study, DMD HIDEMs were transduced with inducible MyoD-ER LV 
vectors before or after the transfection with the PB transposons and myogenic 
differentiation was subsequently induced by tamoxifen. The ability of the 
genetically corrected DMD HIDEMs to engraft in skeletal muscle and produce the 
PB-mediated full-length human dystrophin upon differentiation in vivo was 
validated in immunodeficient dystrophic scid/mdx mice. Upon tamoxifen 
administration and intra-muscular cell transplantation, the presence of human cell 
nuclei and the restoration of the dystrophin expression were detected in the fiber 
membrane of the transplanted muscles by immunofluorescence staining. These 
results establish a proof of concept for a gene therapy platform based on the 
combination of non-viral vectors able to deliver the full-length human dystrophin 
and transplantable DMD patient-specific iPSC derived myogenic cells. 
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Nevertheless, previous studies have shown that the engraftment of HIDEMs 
upon intra-muscular injection in immunodeficient dystrophic mouse models is 
less efficient (i.e. five to six fold less) compared to when mouse counterpart (so 
called MIDEMs, mouse iPSC-derived mesoangioblast-like cells) is employed 
(Gerli et al., 2014; Tedesco et al., 2012). This reflects the species-specific 
differences in survival, migration and differentiation that depend largely on the 
interaction of the transplanted cells with the host microenvironment (Maffioletti et 
al., 2015). On the other hand, studies based on murine muscle stem/progenitor 
cells -or their cognate myogenic ESC/iPSC derivatives may not necessarily 
replicate all of the features of their human counterparts in a clinical setting. 
Therefore, further in vivo studies employing the use of dystrophic mouse models 
with a more profound immune deficiency than the mild model of mdx (i.e. 
combined lack of T, B and NK cells; (Arpke et al., 2013; Vallese et al., 2013)) are 
needed to better investigate the efficiency and efficacy of the xenogenic 
engraftment of the genetically corrected DMD HIDEMs upon intra-muscle and 
intra-arterial transplantation. The use of an appropriate immunodeficient 
dystrophic mouse model to test genetically corrected DMD HIDEMs would 
increase the efficiency of engraftment and the stable expression of the 
therapeutic protein, thus providing valuable information about their application in 
therapy approaches of muscular dystrophies (Tedesco et al., 2012). 
 
Though genomic integration of PB transposons is required for sustained 
expression in dividing and differentiating stem/progenitor cells, it could raise 
some concerns related to the risk of insertional oncogenesis by potentially 
activating oncogenes that are in the vicinity of the integration sites (Biasco et al., 
2012). From a recent study, it emerges that PB transposons exhibit a random 
integration pattern in the genome of murine mesoangioblasts suggesting that in 
these cells they do not preferentially integrate into genes and their regulatory 
regions (Ley et al., 2014). However, further investigation on larger sampling is 
needed. This risk of insertional oncogenesis could be even minimized by 
retargeting PB-mediated integration into potential ‘safe harbor’ loci (Kettlun et al., 
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2011; Wilson and George, 2010). However, it is reassuring that the PB 
transposon copy number detected in the present study fell within an acceptable 
and relatively safe range of genomic integrations per cell (i.e. 0.5-1.7 copies per 
diploid genome), in accordance with the European medicines agency guidelines  
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general
_content_000410.jsp&mid=WC0b01ac058002958d). 
 
Notably, in a tumor formation assay we have assessed that DMD HIDEMs 
manipulated with the hyPB transposase and the PB transposons, with or without 
MyoD-ER LV infection, do not generate tumors. This is consistent with other 
studies that demonstrated the non-tumorigenic nature of HIDEMs (Tedesco et 
al., 2012). Moreover, the safety profile of the PB transposon system as an 
integrating non-viral system gene delivery tool has been previously validated in 
tumor-prone mouse models (Di Matteo et al., 2014). More exhaustive safety 
studies are needed in sensitive model systems to assess the potential risk of 
insertional oncogenesis using these hyperactive PB transposons when used in 
conjunction with myogenic stem/progenitor cells. 
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Appendix 
 
Figure S1. Isolation and characterization of GRMD MABs. (A) A phase 
contrast image of a muscle biopsy of a GRMD dog during the outgrowth of 
adherent cells with some small, round and refractile poor adherent cells (Scale 
bar 100 µm). (B) Alkaline phosphatase (AP) immunoenzymatic staining 
performed on GRMD cells at passage 5 (P5) to detect AP+ adult pericyte-derived 
stem/progenitor cells (Scale bar 100 µm). (C) FACS analysis on GRMD cells at 
P5 showing the surface marker profile CD44+, CD34-, CD45- typical of adult 
MABs. (D) Bar graphs depicting the decreased transcript levels of markers such 
as PAX7, MYF5, CD56, desmin and the presence of NG2 and PDGFR β 
detected by semi-quantitative RT-PCR. Shown are means±SEM triplicate semi-
quantitative RT-PCR analysis performed for a biological replicate; two-tailed 
unpaired Student’s t-test (***p≤ 0.001; **p≤ 0.01; ns: not significant). (E) Pictures 
of electrophoresis on 2% agarose gel of amplicons from (D). (F) The multilineage 
mesodermal differentiation potential of the isolated GRMD MABs was assessed 
by in vitro differentiation assays into skeletal muscle and (G) smooth muscle. 
(Scale bar 100 µm). Bulk: cell population directly derived from the GRMD muscle 
biopsy; P5: GRMD cells at passage 5; P10: GRMD cells at passage 10; L1: 100 
bp ladder; L2: 1 Kb ladder; S-α Actinin: Sarcomeric-α actinin; MyHC: Myosin 
heavy chain; α -SMA: α -Smooth muscle actin.
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Figure S2. Optimization of the transfection protocol for GRMD MABs. The 
bar graphs represent the percentage of GFP+ of GRMD MABs and the viability at 
72h post-EP when the large size PB-SPc-DYS-Pgk-GFP transposon has been 
used to transfect GRMD MABs together with the hyPB transposase. The empty 
plasmid has been used as control. The use of low dose of plasmids (ratio of 0.32 
pmol transposase DNA: 0.87 pmol transposon DNA) led to a lower but not 
statistically significant percentage of GFP+ cells when compared to the higher 
dose of plasmid (0.63 pmol transposase DNA: 1.74 pmol transposon DNA). On 
the other hand, it consistently increases the viability of transfected cells thus 
providing an optimized condition for electroporation of the large size PB-SPc-
DYS-Pgk-GFP transposon into GRMD MABs. Results were presented as 
mean±SEM of three independent biological replicates; two-tailed unpaired 
Student’s t-test (***p≤ 0.001; *p≤ 0.05; ns: not significant).  
 
 
 170 
Figure S3. Immunostaining on differentiated GRMD MABs transposed with 
hyPB + PB-Pgk-GFP. At 21 days post-EP, GRMD MABs transposed with hyPB 
+ PB-Pgk-GFP were induced to differentiate in skeletal muscle in vitro, upon 
MyoD-ER(T) overexpression and 6 days in conditioning medium. The PB-
transposon mediated GFP expression was detected by IF, together with the 
MyHC expression in multinucleated myotubes. In contrast, the control GRMD 
MABs co-transfected with the empty plasmid that does not encode any 
transposase and the same transposon did not show any GFP expression. The 
nuclei were stained with Hoechst (Scale bar 100 µm). 
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Figure S4. RT-PCR on full-length human dystrophin transcript in 
genetically corrected DMD HIDEMMYOD cells. Picture of an RT-PCR performed 
on differentiated DMD HIDEMMYOD cells that had undergone transposition after 
co-transfection with hyPB and PB-SPc-DYS-Pgk-GFP. Three different primer 
pairs were used that recognize respectively (1) the N-terminal, (2) a central 
region and (3) the C-terminal sequences of the full-length human dystrophin 
transcript, yielding amplicons of 221 bp, 222 bp and 228 bp respectively. A 
schematic representation of the PCR primers relative to the different regions of 
the dystrophin transcript is depicted above the picture. As negative control, 
differentiated untreated DMD HIDEMMYOD cells were used. HIDEMMYOD cells from 
a healthy donor (HD) and differentiated in myotubes were employed as a positive 
control; the primer pairs DYS listed in Table 5 have been used for this sample. L: 
50 bp ladder. 
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